Minesh P Mehta

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4699731/publications.pdf

Version: 2024-02-01

679 papers	52,567 citations	1163 111 h-index	1851 209 g-index
748 all docs	748 docs citations	748 times ranked	28929 citing authors

#	Article	IF	Citations
1	Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trial. Neuro-Oncology, 2023, 25, 339-350.	0.6	35
2	Designing Clinical Trials for Combination Immunotherapy: A Framework for Glioblastoma. Clinical Cancer Research, 2022, 28, 585-593.	3.2	18
3	Glioblastoma Clinical Trials: Current Landscape and Opportunities for Improvement. Clinical Cancer Research, 2022, 28, 594-602.	3.2	67
4	Dose-Escalated Magnetic Resonance Imageâ€"Guided Abdominopelvic Reirradiation With Continuous Intrafraction Visualization, Soft Tissue Tracking, and Automatic Beam Gating. Advances in Radiation Oncology, 2022, 7, 100840.	0.6	6
5	CT-guided versus MR-guided radiotherapy: Impact on gastrointestinal sparing in adrenal stereotactic body radiotherapy. Radiotherapy and Oncology, 2022, 166, 101-109.	0.3	20
6	Relationship between insurance status and interhospital transfers among cancer patients in the United States. BMC Cancer, 2022, 22, 121.	1.1	3
7	Graded Prognostic Assessment (GPA) for Patients With Lung Cancer and Brain Metastases: Initial Report of the Small Cell Lung Cancer GPA and Update of the Non-Small Cell Lung Cancer GPA Including the Effect of Programmed Death Ligand 1 and Other Prognostic Factors. International Journal of Radiation Oncology Biology Physics, 2022, 114, 60-74.	0.4	33
8	Evaluation of the impact of pre-operative stereotactic radiotherapy on the acute changes in histopathologic and immune marker profiles of brain metastases. Scientific Reports, 2022, 12, 4567.	1.6	8
9	Hospitalization rates from radiotherapy complications in the United States. Scientific Reports, 2022, 12, 4371.	1.6	5
10	Feasibility of Tumor Treating Fields with Pemetrexed and Platinum-Based Chemotherapy for Unresectable Malignant Pleural Mesothelioma: Single-Center, Real-World Data. Cancers, 2022, 14, 2020.	1.7	7
11	Brain metastases: A Society for Neuro-Oncology (SNO) consensus review on current management and future directions. Neuro-Oncology, 2022, 24, 1613-1646.	0.6	39
12	Implementation Strategies to Increase Clinical Trial Enrollment in a Community-Academic Partnership and Impact on Hispanic Representation: An Interrupted Time Series Analysis. JCO Oncology Practice, 2022, 18, e780-e785.	1.4	11
13	RONC-13. Change in hippocampus volume as a function of radiation dose: Results from a prospective trial with standardized imaging and morphometric evaluation. Neuro-Oncology, 2022, 24, i179-i179.	0.6	1
14	Dedicated isotropic 3-D T1 SPACE sequence imaging for radiosurgery planning improves brain metastases detection and reduces the risk of intracranial relapse. Radiotherapy and Oncology, 2022, 173, 84-92.	0.3	6
15	Pulsed-Reduced Dose Rate (PRDR) Radiotherapy for Recurrent Primary Central Nervous System Malignancies: Dosimetric and Clinical Results. Cancers, 2022, 14, 2946.	1.7	2
16	Joint Final Report of EORTC 26951 and RTOG 9402: Phase III Trials With Procarbazine, Lomustine, and Vincristine Chemotherapy for Anaplastic Oligodendroglial Tumors. Journal of Clinical Oncology, 2022, 40, 2539-2545.	0.8	23
17	Zero Setup Margin Mask versus Frame Immobilization during Gamma KnifeÂ® Iconâ„¢ Stereotactic Radiosurgery for Brain Metastases. Cancers, 2022, 14, 3392.	1.7	5
18	Prevalence and Inpatient Hospital Outcomes of Malignancy-Related Ascites in the United States. American Journal of Hospice and Palliative Medicine, 2021, 38, 47-53.	0.8	5

#	Article	IF	Citations
19	Neurocognitive, symptom, and health-related quality of life outcomes of a randomized trial of bevacizumab for newly diagnosed glioblastoma (NRG/RTOG 0825). Neuro-Oncology, 2021, 23, 1125-1138.	0.6	10
20	Systematic review and meta-analysis of breast cancer brain metastasis and primary tumor receptor expression discordance. Neuro-Oncology Advances, 2021, 3, vdab010.	0.4	15
21	Case report of visual biofeedback-driven, magnetic resonance-guided single-fraction SABR in breath hold for early stage nonâ€"small-cell lung cancer. Medical Dosimetry, 2021, 46, 247-252.	0.4	7
22	Contribution of PET imaging to radiotherapy planning and monitoring in glioma patients - a report of the PET/RANO group. Neuro-Oncology, 2021, 23, 881-893.	0.6	75
23	Novel Radiation Approaches. Neurosurgery Clinics of North America, 2021, 32, 211-223.	0.8	7
24	Regression of Intracranial Meningiomas Following Treatment with Cabozantinib. Current Oncology, 2021, 28, 1537-1543.	0.9	4
25	Expanding the Utilization of Rectal Spacer Hydrogel for Larger Prostate Glands (>80 cc): Feasibility and Dosimetric Outcomes. Advances in Radiation Oncology, 2021, 6, 100651.	0.6	3
26	Meta-Analysis of Survival and Development of a Prognostic Nomogram for Malignant Pleural Mesothelioma Treated with Systemic Chemotherapy. Cancers, 2021, 13, 2186.	1.7	6
27	Stereotactic MR-guided online adaptive radiotherapy reirradiation (SMART reRT) for locally recurrent pancreatic adenocarcinoma: A case report. Medical Dosimetry, 2021, 46, 384-388.	0.4	5
28	Assessment of extracranial metastatic disease in patients with brain metastases: How much effort is needed in the context of evolving survival prediction models?. Radiotherapy and Oncology, 2021, 159, 17-20.	0.3	7
29	Integration of Systemic Therapy and Stereotactic Radiosurgery for Brain Metastases. Cancers, 2021, 13, 3682.	1.7	14
30	Systematic review of combinations of targeted or immunotherapy in advanced solid tumors. , 2021, 9, e002459.		41
31	Impact of MRI timing on tumor volume and anatomic displacement for brain metastases undergoing stereotactic radiosurgery. Neuro-Oncology Practice, 2021, 8, 674-683.	1.0	3
32	Effect of Postoperative Radiation Therapy Timing on Survival in Pediatric and Young Adult Ependymoma. Advances in Radiation Oncology, 2021, 6, 100691.	0.6	1
33	Cross-sectional survey of patients, caregivers, and physicians on diagnosis and treatment of brain metastases. Neuro-Oncology Practice, 2021, 8, 662-673.	1.0	6
34	Long-Term Report of a Comprehensive Molecular and Genomic Analysis in NRG Oncology/RTOG 0424: A Phase II Study of Radiation and Temozolomide in High-Risk Grade II Glioma. JCO Precision Oncology, 2021, 5, 1397-1407.	1.5	6
35	RADI-11. Evaluating the Tissue Effects of Dose-escalated Pre-operative Stereotactic Radiotherapy for Resectable Brain Metastasis. Neuro-Oncology Advances, 2021, 3, iii20-iii20.	0.4	0
36	OTHR-07. Systematic Review and Meta-analysis of Lung Cancer Brain Metastasis and Primary Tumor PD-L1 Expression Discordance. Neuro-Oncology Advances, 2021, 3, iii15-iii16.	0.4	0

#	Article	IF	Citations
37	A prospective multidisciplinary review of radiotherapy processes during the telemedicine era.. Journal of Clinical Oncology, 2021, 39, 282-282.	0.8	0
38	A multi-center prospective study of re-irradiation with bevacizumab and temozolomide in patients with bevacizumab refractory recurrent high-grade gliomas. Journal of Neuro-Oncology, 2021, 155, 297-306.	1.4	5
39	Systematic evaluation and plan quality assessment of the LeksellÂ® gamma knifeÂ® lightning dose optimizer. Medical Dosimetry, 2021, , .	0.4	10
40	Systematic review and meta-analysis of lung cancer brain metastasis and primary tumor receptor expression discordance. Discover Oncology, 2021, 12, 48.	0.8	7
41	Independently validated sex-specific nomograms for predicting survival in patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825. Journal of Neuro-Oncology, 2021, 155, 363-372.	1.4	11
42	Systematic review and meta-analysis of PD-L1 expression discordance between primary tumor and lung cancer brain metastasis. Neuro-Oncology Advances, 2021, 3, vdab166.	0.4	5
43	Factors associated with unplanned readmissions and costs following resection of brain metastases in the United States. Scientific Reports, 2021, 11, 22152.	1.6	3
44	Clinical Trial Eligibility Criteria and Recently Approved Cancer Therapies for Patients With Brain Metastases. Frontiers in Oncology, 2021, 11, 780379.	1.3	7
45	Evaluation of a prospective radiation oncology departmental team review process using standardized simulation directives. Radiotherapy and Oncology, 2021, , .	0.3	1
46	High-risk Meningioma: Initial Outcomes From NRG Oncology/RTOG 0539. International Journal of Radiation Oncology Biology Physics, 2020, 106, 790-799.	0.4	108
47	Phase I/II study of sorafenib in combination with erlotinib for recurrent glioblastoma as part of a 3-arm sequential accrual clinical trial: NABTC 05-02. Neuro-Oncology Advances, 2020, 2, vdaa124.	0.4	5
48	Radiation therapy alone versus radiation therapy plus radiofrequency ablation/vertebral augmentation for spine metastasis: study protocol for a randomized controlled trial. Trials, 2020, 21, 964.	0.7	4
49	Comprehensive Genomic Analysis in NRG Oncology/RTOG 9802: A Phase III Trial of Radiation Versus Radiation Plus Procarbazine, Lomustine (CCNU), and Vincristine in High-Risk Low-Grade Glioma. Journal of Clinical Oncology, 2020, 38, 3407-3417.	0.8	107
50	Radiotherapy innovations to optimize brain metastases control. Neuro-Oncology, 2020, 22, 1715-1717.	0.6	0
51	Inpatient Palliative Care Use Among Critically Ill Brain Metastasis Patients in the United States. American Journal of Clinical Oncology: Cancer Clinical Trials, 2020, 43, 806-812.	0.6	2
52	Survival in Patients With Brain Metastases: Summary Report on the Updated Diagnosis-Specific Graded Prognostic Assessment and Definition of the Eligibility Quotient. Journal of Clinical Oncology, 2020, 38, 3773-3784.	0.8	223
53	Effectiveness of Radiofrequency Ablation in the Treatment of Painful Osseous Metastases: A Correlation Meta-Analysis with Machine Learning Cluster Identification. Journal of Vascular and Interventional Radiology, 2020, 31, 1753-1762.	0.2	13
54	A risk model for prediction of 30-day readmission rates after surgical treatment for colon cancer. International Journal of Colorectal Disease, 2020, 35, 1529-1535.	1.0	2

#	Article	IF	Citations
55	Extreme hypofractionation for newly diagnosed glioblastoma: rationale, dose, techniques, and outcomes. Neuro-Oncology, 2020, 22, 1062-1064.	0.6	0
56	NRG/RTOG 1122: A phase 2, doubleâ€blinded, placeboâ€controlled study of bevacizumab with and without trebananib in patients with recurrent glioblastoma or gliosarcoma. Cancer, 2020, 126, 2821-2828.	2.0	25
57	Putative Abscopal Effect in Three Patients Treated by Combined Radiotherapy and Modulated Electrohyperthermia. Frontiers in Oncology, 2020, 10, 254.	1.3	19
58	Early imaging marker of progressing glioblastoma: a window of opportunity. Journal of Neuro-Oncology, 2020, 148, 629-640.	1.4	3
59	Estrogen/progesterone receptor and HER2 discordance between primary tumor and brain metastases in breast cancer and its effect on treatment and survival. Neuro-Oncology, 2020, 22, 1359-1367.	0.6	49
60	Beyond an Updated Graded Prognostic Assessment (Breast GPA): A Prognostic Index and Trends in Treatment and Survival in Breast Cancer Brain Metastases From 1985 to Today. International Journal of Radiation Oncology Biology Physics, 2020, 107, 334-343.	0.4	81
61	Biological activity of weekly ONC201 in adult recurrent glioblastoma patients. Neuro-Oncology, 2020, 22, 94-102.	0.6	53
62	Hippocampal Avoidance During Whole-Brain Radiotherapy Plus Memantine for Patients With Brain Metastases: Phase III Trial NRG Oncology CC001. Journal of Clinical Oncology, 2020, 38, 1019-1029.	0.8	483
63	Phase 2 Study of a Temozolomide-Based Chemoradiation Therapy Regimen for High-Risk, Low-Grade Gliomas: Long-Term Results of Radiation Therapy Oncology Group 0424. International Journal of Radiation Oncology Biology Physics, 2020, 107, 720-725.	0.4	33
64	Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. Neuro-Oncology, 2020, 22, 1073-1113.	0.6	543
65	Pediatric bithalamic gliomas have a distinct epigenetic signature and frequent EGFR exon 20 insertions resulting in potential sensitivity to targeted kinase inhibition. Acta Neuropathologica, 2020, 139, 1071-1088.	3.9	50
66	Optimizing eligibility criteria and clinical trial conduct to enhance clinical trial participation for primary brain tumor patients. Neuro-Oncology, 2020, 22, 601-612.	0.6	23
67	Investigating Low-Dose Thoracic Radiation as a Treatment for COVID-19 Patients to Prevent Respiratory Failure. Radiation Research, 2020, 194, 1.	0.7	16
68	A Comprehensive Analysis of a Prospective Multidisciplinary Peer Review Process Before Radiation Therapy Simulation. Practical Radiation Oncology, 2020, 11, e366-e375.	1.1	1
69	Preoperative Vs Postoperative Radiosurgery For Resected Brain Metastases: A Review. Neurosurgery, 2019, 84, 19-29.	0.6	50
70	Pretreatment Volume of MRI-Determined White Matter Injury Predicts Neurocognitive Decline After Hippocampal Avoidant Whole-Brain Radiation Therapy for Brain Metastases: Secondary Analysis of NRG Oncology Radiation Therapy Oncology Group 0933. Advances in Radiation Oncology, 2019, 4, 579-586.	0.6	17
71	Estimating survival in patients with gastrointestinal cancers and brain metastases: An update of the graded prognostic assessment for gastrointestinal cancers (GI-GPA). Clinical and Translational Radiation Oncology, 2019, 18, 39-45.	0.9	26
72	Epidermal growth factor receptor (EGFR) amplification rates observed in screening patients for randomized trials in glioblastoma. Journal of Neuro-Oncology, 2019, 144, 205-210.	1.4	24

#	Article	IF	Citations
73	Barriers to accrual and enrollment in brain tumor trials. Neuro-Oncology, 2019, 21, 1100-1117.	0.6	36
74	Phase III METIS study: Tumor treating fields (150 kHz) and radiosurgery for supra- and/or infratentorial brain metastases (1-10) from non-small cell lung cancer (NSCLC). Annals of Oncology, 2019, 30, ii70-ii71.	0.6	3
75	The association between BMI and BSAâ€"temozolomide-induced myelosuppression toxicities: a correlative analysis of NRG oncology RTOG 0525. Neuro-Oncology Practice, 2019, 6, 473-478.	1.0	5
76	Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201. Journal of Neuro-Oncology, 2019, 145, 97-105.	1.4	125
77	Randomized Phase II Trial of Re-Irradiation and Concurrent Bevacizumab versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma (NRG Oncology/RTOG 1205): Initial Outcomes and RT Plan Quality Report. International Journal of Radiation Oncology Biology Physics, 2019, 105, S78.	0.4	33
78	Significant Preservation of Neurocognitive Function (NCF) and Patient-Reported Symptoms with Hippocampal Avoidance (HA) during Whole-Brain Radiotherapy (WBRT) for Brain Metastases: Final Results of Nrg Oncology CC001. International Journal of Radiation Oncology Biology Physics, 2019, 105, S12-S13.	0.4	4
79	Letter: When Less is More: Dexamethasone Dosing for Brain Tumors. Neurosurgery, 2019, 85, E607-E608.	0.6	20
80	First clinical experience with DRD2/3 antagonist ONC201 in H3 K27Mâ€"mutant pediatric diffuse intrinsic pontine glioma: a case report. Journal of Neurosurgery: Pediatrics, 2019, 23, 719-725.	0.8	52
81	Basic principles of brain tumor radiotherapy. , 2019, , 245-262.		1
82	The Complexity of Managing Large Brain Metastasis. International Journal of Radiation Oncology Biology Physics, 2019, 104, 483-484.	0.4	6
83	Glioblastoma. , 2019, , 237-247.		0
84	WHO II and III Gliomas. , 2019, , 217-236.		1
85	Updates in the management of intradural spinal cord tumors: a radiation oncology focus. Neuro-Oncology, 2019, 21, 707-718.	0.6	18
86	Defining an Intermediate-risk Group for Low-grade Glioma: A National Cancer Database Analysis. Anticancer Research, 2019, 39, 2911-2918.	0.5	8
87	NRG brain tumor specialists consensus guidelines for glioblastoma contouring. Journal of Neuro-Oncology, 2019, 143, 157-166.	1.4	58
88	Survival and prognostic factors in patients with gastrointestinal cancers and brain metastases: have we made progress?. Translational Research, 2019, 208, 63-72.	2.2	13
89	Management of patients with brain metastases from non-small cell lung cancer and adverse prognostic features: multi-national radiation treatment recommendations are heterogeneous. Radiation Oncology, 2019, 14, 33.	1.2	24
90	Phase 2 Study of Radiation Therapy Plus Low-Dose Temozolomide Followed by Temozolomide and Irinotecan for Glioblastoma: NRG Oncology RTOG Trial 0420. International Journal of Radiation Oncology Biology Physics, 2019, 103, 878-886.	0.4	10

#	Article	IF	Citations
91	INNV-33. BARRIERS TO ACCRUAL AND ENROLLMENT IN BRAIN TUMOR TRIALS. Neuro-Oncology, 2019, 21, vi137-vi137.	0.6	18
92	ACTR-32. NRG ONCOLOGY RTOG 1205: RANDOMIZED PHASE II TRIAL OF CONCURRENT BEVACIZUMAB AND RE-IRRADIATION VS. BEVACIZUMAB ALONE AS TREATMENT FOR RECURRENT GLIOBLASTOMA. Neuro-Oncology, 2019, 21, vi20-vi20.	0.6	11
93	MGMT promoter methylation status testing to guide therapy for glioblastoma: refining the approach based on emerging evidence and current challenges. Neuro-Oncology, 2019, 21, 167-178.	0.6	173
94	Low-Grade Glioma Radiotherapy Treatment and Trials. Neurosurgery Clinics of North America, 2019, 30, 111-118.	0.8	60
95	Influence of Residual Disease Following Surgical Resection in Newly Diagnosed Glioblastoma on Clinical, Neurocognitive, and Patient Reported Outcomes. Neurosurgery, 2019, 84, 66-76.	0.6	7
96	Tumor subtype and other prognostic factors in breast cancer patients with brain metastases: The updated graded prognostic assessment (Breast-GPA).. Journal of Clinical Oncology, 2019, 37, 1079-1079.	0.8	4
97	Updated predictive analysis of the WHO-defined molecular subgroups of low-grade gliomas within the high-risk treatment arms of NRG Oncology/RTOG 9802.. Journal of Clinical Oncology, 2019, 37, 2002-2002.	0.8	6
98	NRG Oncology CC001: A phase III trial of hippocampal avoidance (HA) in addition to whole-brain radiotherapy (WBRT) plus memantine to preserve neurocognitive function (NCF) in patients with brain metastases (BM).. Journal of Clinical Oncology, 2019, 37, 2009-2009.	0.8	31
99	Barriers to accrual and enrollment in brain tumor trials.. Journal of Clinical Oncology, 2019, 37, 2024-2024.	0.8	1
100	Single agent ONC201 in adult recurrent H3 K27M-mutant glioma.. Journal of Clinical Oncology, 2019, 37, 3005-3005.	0.8	3
101	Insight into the brain metastasis journey: Initial survey results from patients and caregivers.. Journal of Clinical Oncology, 2019, 37, 2069-2069.	0.8	0
102	Short delay in initiation of radiotherapy for patients with glioblastoma-effect of concurrent chemotherapy: a secondary analysis from the NRG Oncology/Radiation Therapy Oncology Group database. Neuro-Oncology, 2018, 20, 966-974.	0.6	33
103	Role of Radiosensitizers in Radiation Treatment of Gliomas. Progress in Neurological Surgery, 2018, 31, 102-115.	1.3	3
104	A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: results of NRG Oncology RTOG 0913. Neuro-Oncology, 2018, 20, 666-673.	0.6	108
105	Repeat reirradiation of the spinal cord: multi-national expert treatment recommendations. Strahlentherapie Und Onkologie, 2018, 194, 365-374.	1.0	17
106	Clinical trial design for local therapies for brain metastases: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group. Lancet Oncology, The, 2018, 19, e33-e42.	5.1	42
107	Control versus cognition: the changing paradigm of adjuvant therapy for resected brain metastasis. Neuro-Oncology, 2018, 20, 2-3.	0.6	7
108	Consolidative Whole-Brain Radiation Therapy Versus Autologous Stem Cell Transplant for Primary Central Nervous System Lymphoma: A Large Dose of Perspective and Perhaps a Lower Dose of Radiation Are in Order. International Journal of Radiation Oncology Biology Physics, 2018, 102, 59-60.	0.4	3

#	Article	IF	Citations
109	Prognostic and predictive factors in patients with brain metastases from solid tumors: A review of published nomograms. Critical Reviews in Oncology/Hematology, 2018, 126, 13-18.	2.0	51
110	Preradiation Chemotherapy for Adult High-risk Medulloblastoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 588-594.	0.6	17
111	Brain Metastases in Lung Cancer With Targetable Mutationsâ€"Reply. JAMA Oncology, 2018, 4, 422.	3.4	0
112	Phase I study of sorafenib and tipifarnib for recurrent glioblastoma: NABTC 05-02. Journal of Neuro-Oncology, 2018, 136, 79-86.	1.4	21
113	Investigating the Effect of Reirradiation or Systemic Therapy in Patients With Glioblastoma After Tumor Progression: A Secondary Analysis of NRG Oncology/Radiation Therapy Oncology Group Trial 0525. International Journal of Radiation Oncology Biology Physics, 2018, 100, 38-44.	0.4	49
114	Intermediate-risk meningioma: initial outcomes from NRG Oncology RTOG 0539. Journal of Neurosurgery, 2018, 129, 35-47.	0.9	178
115	The Evolving Role of Tumor Treating Fields in Managing Glioblastoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 191-196.	0.6	48
116	Dosimetric Impact of Large Displacement of the Metal Port of the Tissue Expander in Intensity Modulated Proton Therapy. International Journal of Radiation Oncology Biology Physics, 2018, 102, S183.	0.4	0
117	Pencil beam scanning versus passively scattered proton therapy for unresectable pancreatic cancer. Journal of Gastrointestinal Oncology, 2018, 9, 687-693.	0.6	26
118	Survival and Prognostic Factors in Patients with Gastrointestinal Cancers and Brain Metastases. International Journal of Radiation Oncology Biology Physics, 2018, 102, e314-e315.	0.4	0
119	ACTR-34. INTEGRATED CLINICAL EXPERIENCE WITH ONC201 IN PREVIOUSLY-TREATED H3 K27M-MUTANT GLIOMA PATIENTS. Neuro-Oncology, 2018, 20, vi19-vi19.	0.6	3
120	Preservation of Neurocognitive Function (NCF) with Conformal Avoidance of the Hippocampus during Whole-Brain Radiotherapy (HA-WBRT) for Brain Metastases: Preliminary Results of Phase III Trial NRG Oncology CC001. International Journal of Radiation Oncology Biology Physics, 2018, 102, 1607.	0.4	47
121	Postoperative Management of Resected Brain Metastases: When Can Radiotherapy Be Deferred?. Journal of Clinical Oncology, 2018, 36, 3277-3281.	0.8	0
122	What is the evidence for the clinical value of SBRT in cancer of the cervix?. Reports of Practical Oncology and Radiotherapy, 2018, 23, 574-579.	0.3	13
123	Association of MGMT Promoter Methylation Status With Survival Outcomes in Patients With High-Risk Glioma Treated With Radiotherapy and Temozolomide. JAMA Oncology, 2018, 4, 1405.	3.4	141
124	Effect of Targeted Therapies on Prognostic Factors, Patterns of Care, and Survival in Patients With Renal Cell Carcinoma and Brain Metastases. International Journal of Radiation Oncology Biology Physics, 2018, 101, 845-853.	0.4	22
125	Estimating survival for renal cell carcinoma patients with brain metastases: an update of the Renal Graded Prognostic Assessment tool. Neuro-Oncology, 2018, 20, 1652-1660.	0.6	47
126	Onco-metabolism: defining the prognostic significance of obesity and diabetes in women with brain metastases from breast cancer. Breast Cancer Research and Treatment, 2018, 172, 221-230.	1.1	18

#	Article	IF	Citations
127	Omitting radiosurgery in melanoma brain metastases: a drastic and dangerous de-escalation. Lancet Oncology, The, 2018, 19, e366.	5.1	10
128	Prognostic models for patients with brain metastases after stereotactic radiosurgery with or without whole brain radiotherapy: a validation study. Journal of Neuro-Oncology, 2018, 140, 341-349.	1.4	12
129	Treatment recommendations for elderly patients with newly diagnosed glioblastoma lack worldwide consensus. Journal of Neuro-Oncology, 2018, 140, 421-426.	1.4	22
130	NRG BN002: Phase I study of checkpoint inhibitors anti-CTLA-4, anti-PD-1, the combination in patients with newly diagnosed glioblastoma.. Journal of Clinical Oncology, 2018, 36, 2053-2053.	0.8	5
131	Impact of apolipoprotein E (APOE) genotype on neurocognitive function (NCF) in patients with brain metastasis (BM): An analysis of NRG Oncologyâ€™s RTOG 0614.. Journal of Clinical Oncology, 2018, 36, 2065-2065.	0.8	4
132	Intratumoral activity of ONC201 in adult recurrent glioblastoma patients.. Journal of Clinical Oncology, 2018, 36, e14034-e14034.	0.8	2
133	Recent advances in managing brain metastasis. F1000Research, 2018, 7, 1772.	0.8	63
134	Temozolomide, sirolimus and chloroquine is a new therapeutic combination that synergizes to disrupt lysosomal function and cholesterol homeostasis in GBM cells. Oncotarget, 2018, 9, 6883-6896.	0.8	37
135	Abstract CT151: TTFields and radiosurgery for 1 to 10 brain metastases from NSCLC in the phase III METIS study. , 2018, , .		0
136	Phase III randomized study of radiation and temozolomide versus radiation and nitrosourea therapy for anaplastic astrocytoma: results of NRG Oncology RTOG 9813. Neuro-Oncology, 2017, 19, now236.	0.6	39
137	An independently validated nomogram for individualized estimation of survival among patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825. Neuro-Oncology, 2017, 19, now208.	0.6	109
138	Molecular-Based Recursive Partitioning Analysis Model for Glioblastoma in the Temozolomide Era. JAMA Oncology, 2017, 3, 784.	3.4	83
139	Cost-effectiveness of prophylactic cranial irradiation with hippocampal avoidance in limited stage small cell lung cancer. Radiotherapy and Oncology, 2017, 122, 411-415.	0.3	18
140	Critical review of the addition of tumor treating fields (TTFields) to the existing standard of care for newly diagnosed glioblastoma patients. Critical Reviews in Oncology/Hematology, 2017, 111, 60-65.	2.0	75
141	A Multi-institutional Analysis of Trimodality Therapy for Esophageal Cancer in Elderly Patients. International Journal of Radiation Oncology Biology Physics, 2017, 98, 820-828.	0.4	28
142	The role of radiation in treating glioblastoma: here to stay. Journal of Neuro-Oncology, 2017, 134, 479-485.	1.4	26
143	The Prognostic Value of BRAF , C-KIT , and NRAS Mutations in Melanoma Patients With Brain Metastases. International Journal of Radiation Oncology Biology Physics, 2017, 98, 1069-1077.	0.4	58
144	Reirradiation of recurrent node-positive non-small cell lung cancer after previous stereotactic radiotherapy for stageÂI disease. Strahlentherapie Und Onkologie, 2017, 193, 515-524.	1.0	13

#	Article	IF	Citations
145	Multi-institutional analysis of radiation modality use and postoperative outcomes of neoadjuvant chemoradiation for esophageal cancer. Radiotherapy and Oncology, 2017, 123, 376-381.	0.3	81
146	The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria. Neuro-Oncology, 2017, 19, 625-635.	0.6	137
147	A phase II trial of arsenic trioxide and temozolomide in combination with radiation therapy for patients with malignant gliomas. Journal of Neuro-Oncology, 2017, 133, 589-594.	1.4	22
148	Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG. Neuro-Oncology, 2017, 19, 1119-1126.	0.6	107
149	P2.06-034 METIS: A Phase 3 Study of Radiosurgery with TTFields for 1-10 Brain Metastases from NSCLC. Journal of Thoracic Oncology, 2017, 12, S1092-S1093.	0.5	0
150	Radiation Therapy for Glioblastoma: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Guideline. Journal of Clinical Oncology, 2017, 35, 361-369.	0.8	109
151	The Changing Role of Whole-Brain Radiotherapy. JAMA Oncology, 2017, 3, 1021.	3.4	19
152	Estimating Survival in Melanoma Patients With Brain Metastases: An Update of the Graded Prognostic Assessment for Melanoma Using Molecular Markers (Melanoma-molGPA). International Journal of Radiation Oncology Biology Physics, 2017, 99, 812-816.	0.4	163
153	Prognostic Factors in Patients with Renal Cell Carcinoma and Brain Metastases. International Journal of Radiation Oncology Biology Physics, 2017, 99, S169-S170.	0.4	2
154	Multi-institutional external validation of a novel glioblastoma prognostic nomogram incorporating MGMT methylation. Journal of Neuro-Oncology, 2017, 134, 331-338.	1.4	21
155	Radiation Therapy in the Treatment of Low Grade Gliomas. , 2017, , 579-594.		0
156	NRG oncology RTOG 0625: a randomized phase II trial of bevacizumab with either irinotecan or dose-dense temozolomide in recurrent glioblastoma. Journal of Neuro-Oncology, 2017, 131, 193-199.	1.4	55
157	Multi-Institutional Experience of Stereotactic Ablative Radiation Therapy for Stage I Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2017, 97, 362-371.	0.4	78
158	Establishing Evidence-Based Indications for Proton Therapy: An Overview of Current Clinical Trials. International Journal of Radiation Oncology Biology Physics, 2017, 97, 228-235.	0.4	61
159	Veliparib in combination with whole-brain radiation therapy for patients with brain metastases from non-small cell lung cancer: results of a randomized, global, placebo-controlled study. Journal of Neuro-Oncology, 2017, 131, 105-115.	1.4	61
160	Estimating Survival in Patients With Lung Cancer and Brain Metastases. JAMA Oncology, 2017, 3, 827.	3.4	543
161	State of the art: the evolving role of RT in combined modality therapy for GBM. Journal of Neuro-Oncology, 2017, 134, 477-478.	1.4	0
162	Rectal dose to prostate cancer patients treated with proton therapy with or without rectal spacer. Journal of Applied Clinical Medical Physics, 2017, 18, 32-39.	0.8	13

#	Article	IF	Citations
163	METIS: A phase 3 study of radiosurgery with TTFields for 1-10 brain metastases from NSCLC.. Journal of Clinical Oncology, 2017, 35, TPS9106-TPS9106.	0.8	3
164	Genetic landscape of extreme responders with anaplastic oligodendroglioma. Oncotarget, 2017, 8, 35523-35531.	0.8	8
165	METIS: A phase III study of radiosurgery with TTFields for 1-10 brain metastases from NSCLC. Annals of Oncology, 2016, 27, vi113.	0.6	0
166	Reply to M.C. Chamberlain. Journal of Clinical Oncology, 2016, 34, 4057-4057.	0.8	0
167	Treatment of Adult Lower-Grade Glioma in the Era of Genomic Medicine. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, 75-81.	1.8	17
168	Clinical outcomes and toxicities of proton radiotherapy for gastrointestinal neoplasms: a systematic review. Journal of Gastrointestinal Oncology, 2016, 7, 644-664.	0.6	56
169	Clinical ramifications of â€œgenomic stagingâ€•of low-grade gliomas. Journal of Neuro-Oncology, 2016, 129, 195-199.	1.4	11
170	Updates in the management of brain metastases. Neuro-Oncology, 2016, 18, 1043-1065.	0.6	209
171	A systematic review of the cost and costâ€•effectiveness studies of proton radiotherapy. Cancer, 2016, 122, 1483-1501.	2.0	162
172	Stereotactic Radiosurgery for Treatment of Brain Metastases. Journal of Oncology Practice, 2016, 12, 703-712.	2.5	42
173	Caloric restriction coupled with radiation decreases metastatic burden in triple negative breast cancer. Cell Cycle, 2016, 15, 2265-2274.	1.3	67
174	Phase I and II Study of Induction Chemotherapy With Methotrexate, Rituximab, and Temozolomide, Followed By Whole-Brain Radiotherapy and Postirradiation Temozolomide for Primary CNS Lymphoma: NRG Oncology RTOG 0227. Journal of Clinical Oncology, 2016, 34, 1620-1625.	0.8	121
175	Proton therapy for paediatric CNS tumours â€" improving treatment-related outcomes. Nature Reviews Neurology, 2016, 12, 334-345.	4.9	50
176	Clinical Outcomes and Toxicity of Proton Radiotherapy for Breast Cancer. Clinical Breast Cancer, 2016, 16, 145-154.	1.1	55
177	Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma. New England Journal of Medicine, 2016, 374, 1344-1355.	13.9	814
178	Neural stem cells, the subventricular zone and radiotherapy: implications for treating glioblastoma. Journal of Neuro-Oncology, 2016, 128, 207-216.	1.4	32
179	The Effect of Gene Alterations and Tyrosine Kinase Inhibition on Survival and Cause of Death in Patients With Adenocarcinoma of the Lung and Brain Metastases. International Journal of Radiation Oncology Biology Physics, 2016, 96, 406-413.	0.4	84
180	Improving Radiation Oncology Residency Structure: A Multi-Institutional Survey Study. International Journal of Radiation Oncology Biology Physics, 2016, 96, E417.	0.4	0

#	Article	IF	Citations
181	Radiomics for Survival Analysis and Prediction in Glioblastoma (GBM)â€"A Preliminary Study. International Journal of Radiation Oncology Biology Physics, 2016, 96, E106-E107.	0.4	2
182	Low Levels of Acute Toxicity Associated With Proton Therapy for Low-Grade Glioma: A Proton Collaborative Group Study. International Journal of Radiation Oncology Biology Physics, 2016, 96, E135.	0.4	21
183	Impact of Age on Early Volumetric Changes in Adults with Low-Grade or Benign Intracranial Neoplasms Treated With External Beam Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2016, 96, E83.	0.4	0
184	A Mutation and Prognostic Biomarker Study in Grade II and III Gliomas Utilizing a Combined Cohort of NRG Oncology/RTOG 9802 and 9813. International Journal of Radiation Oncology Biology Physics, 2016, 96, S91.	0.4	0
185	Proton Therapy in the USA From 2012 to 2014â€"Increasing Treatment of Pediatric, Lung, Head and Neck, Gastrointestinal, and Breast Cancers, But No Increase in Prostate Cancer Treatments: A Study From the National Association for Proton Therapy. International Journal of Radiation Oncology Biology Physics, 2016, 96, S136-S137.	0.4	1
186	The Effect of Gene Mutations on Survival in Patients With Melanoma Following the Development of Brain Metastases. International Journal of Radiation Oncology Biology Physics, 2016, 96, S178.	0.4	1
187	Interobserver Variability in Atlas-Based, Manual Segmentation of the Hippocampus in Patients With Brain Metastases. International Journal of Radiation Oncology Biology Physics, 2016, 96, E130.	0.4	2
188	An Independently Validated Nomogram for Individualized Estimation of Survival Among Patients With Newly Diagnosed Glioblastoma: NRG Oncology/RTOG 0525 and 0825. International Journal of Radiation Oncology Biology Physics, 2016, 96, S92.	0.4	5
189	Multi-institutional Validation of a Novel Glioblastoma Prognostic Nomogram Incorporating MGMT Methylation. International Journal of Radiation Oncology Biology Physics, 2016, 96, S182.	0.4	0
190	Principles of radiation therapy. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2016, 134, 131-147.	1.0	2
191	Brain Metastases. Medical Radiology, 2016, , 337-356.	0.0	0
192	Proton radiotherapy for gynecologic neoplasms. Acta OncolÃ³gica, 2016, 55, 1257-1265.	0.8	20
193	Association between IL28B rs12979860 single nucleotide polymorphism and the frequency of colonic Treg in chronically HCV-infected patients. Archives of Virology, 2016, 161, 3161-3169.	0.9	23
194	Reply to F. Felix et al and M.F. Fay et al. Journal of Clinical Oncology, 2016, 34, 3107-3108.	0.8	2
195	Clinical Outcomes of Patients with Stage II-III Non-Small Cell Lung Cancer (NSCLC) Treated with Proton Beam Therapy (PBT) on the Proton Collaborative Group (PCG) Prospective Registry Trial. International Journal of Radiation Oncology Biology Physics, 2016, 96, E434-E435.	0.4	0
196	Robust Lymph Nodes Proton Scanning Irradiation for Locally Advanced Breast Cancer. International Journal of Radiation Oncology Biology Physics, 2016, 96, E682.	0.4	0
197	Future Directions for Tumor Treating Fields. , 2016, , 117-126.		0
198	Identification of Patients Who Benefit From Bevacizumab in High-Grade Gliomaâ€"An Easy Question Turned Difficult: Treat the Scan or the Patient?. Journal of Clinical Oncology, 2016, 34, 1281-1282.	0.8	6

#	Article	IF	Citations
199	Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma. Journal of Clinical Oncology, 2016, 34, 731-739.	0.8	159
200	Treatment Responses and Survival in IDH1-Mutant Grade II and III Gliomas in NRG Oncology/RTOG 9802 and 9813. International Journal of Radiation Oncology Biology Physics, 2016, 94, 6.	0.4	1
201	Glioblastoma: Radiation treatment margins, how small is large enough?. Practical Radiation Oncology, 2016, 6, 298-305.	1.1	36
202	International Medical Graduates in Radiation Oncology: Historical Trends and Comparison With Other Medical Specialties. International Journal of Radiation Oncology Biology Physics, 2016, 95, 1102-1106.	0.4	8
203	Clinical Outcomes of Proton Radiotherapy for Uveal Melanoma. Clinical Oncology, 2016, 28, e17-e27.	0.6	60
204	What predicts early volumetric edema increase following stereotactic radiosurgery for brain metastases?. Journal of Neuro-Oncology, 2016, 127, 303-311.	1.4	15
205	Pathologic deposition of non-amyloid immunoglobulin in the brain leading to mass effect and neurological deficits. Journal of Clinical Neuroscience, 2016, 30, 143-145.	0.8	3
206	CogState computerized memory tests in patients with brain metastases: secondary endpoint results of NRG Oncology RTOG 0933. Journal of Neuro-Oncology, 2016, 126, 327-336.	1.4	31
207	A randomized phase I/II study of ABT-888 in combination with temozolomide in recurrent temozolomide resistant glioblastoma: an NRG oncology RTOG group study. Journal of Neuro-Oncology, 2016, 126, 309-316.	1.4	57
208	Pathology concordance levels for meningioma classification and grading in NRG Oncology RTOG Trial 0539. Neuro-Oncology, 2016, 18, 565-574.	0.6	91
209	SU-F-R-04: Radiomics for Survival Prediction in Glioblastoma (GBM). Medical Physics, 2016, 43, 3373-3373.	1.6	6
210	Comprehensive mutation analysis in NRG Oncology/RTOG 9813: A phase III trial of RT + TMZ vs RT + nu for anaplastic astrocytoma and mixed anaplastic oligoastrocytoma (Astrocytoma Dominant).. Journal of Clinical Oncology, 2016, 34, 2016-2016.	0.8	18
211	Comprehensive mutation analysis in NRG Oncology/RTOG 9802: A phase III study of RT vs RT + PCV in high-risk low-grade gliomas (LGGs).. Journal of Clinical Oncology, 2016, 34, 2017-2017.	0.8	1
212	Anteriorly Oriented Beam Arrangements with Daily in Vivo Range Verification for Proton Therapy of Prostate Cancer: Rectal Toxicity Rates. International Journal of Particle Therapy, 2016, 2, 509-517.	0.9	7
213	Free Breathing versus Breath-Hold Scanning Beam Proton Therapy and Cardiac Sparing in Breast Cancer. International Journal of Particle Therapy, 2016, 3, 407-413.	0.9	12
214	Treatment of Adult Lower-Grade Glioma in the Era of Genomic Medicine. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 36, 75-81.	1.8	4
215	Context for Protons as Adjunctive Therapy in Neovascular Age-Related Macular Degeneration: A Review. International Journal of Particle Therapy, 2016, 2, 555-569.	0.9	0
216	Genetic landscape of extreme responders with anaplastic oligodendroglioma: NRG Oncology/RTOG 9402.. Journal of Clinical Oncology, 2016, 34, 2054-2054.	0.8	4

#	Article	IF	Citations
217	An independently validated nomogram for individualized estimation of survival among patients with newly diagnosed glioblastoma: NRG oncology/RTOG 0525 and 0825.. Journal of Clinical Oncology, 2016, 34, 2007-2007.	0.8	0
218	SU-F-T-188: A Robust Treatment Planning Technique for Proton Pencil Beam Scanning Cranial Spinal Irradiation. Medical Physics, 2016, 43, 3505-3505.	1.6	0
219	An overview of modern proton therapy. Chinese Clinical Oncology, 2016, 5, 48-48.	0.4	4
220	Gamma Knife Radiosurgery for 5 to 10 Brain Metastases: May Not Be Reasonable as Sole Upfront Treatment. Oncology, 2016, 30, 314, 316-7.	0.4	3
221	RTRB-05DEFINING THE ROLE OF PROPHYLACTIC CRANIAL IRRADIATION IN NSCLC: A SYSTEMATIC REVIEW AND META-ANALYSIS OF THE WORLD'S LITERATURE. Neuro-Oncology, 2015, 17, v196.1-v196.	0.6	2
222	ATCT-22NRG ONCOLOGY/RTOG 1122: PHASE II DOUBLE-BLINDED, PLACEBO-CONTROLLED STUDY OF BEVACIZUMAB WITH OR WITHOUT AMG 386 IN PATIENTS WITH RECURRENT GLIOBLASTOMA OR GLIOSARCOMA. Neuro-Oncology, 2015, 17, v6.2-v6.	0.6	2
223	NCO-14PRE-TREATMENT HIPPOCAMPAL VOLUME PREDICTS NEUROCOGNITIVE FUNCTION (NCF) FOR PATIENTS TREATED WITH HIPPOCAMPAL AVOIDANCE WHOLE BRAIN RADIOTHERAPY (HA-WBRT) FOR BRAIN METASTASES: SECONDARY ANALYSIS OF NRG ONCOLOGY/RTOG 0933. Neuro-Oncology, 2015, 17, v149.1-v149.	0.6	0
224	Proton Beam Therapy Basics. Journal of the American College of Radiology, 2015, 12, 1204-1206.	0.9	1
225	Novel Proton Beam Arrangements for Prostate Cancer Using In Vivo Range Verification May Significantly Reduce the Risk of High Grade Rectal Toxicities. International Journal of Radiation Oncology Biology Physics, 2015, 93, E559-E560.	0.4	1
226	BMET-20RTOG1119 PHASE II RANDOMIZED STUDY OF WHOLE BRAIN RADIOTHERAPY WITH CONCURRENT LAPATINIB IN PATIENTS WITH BRAIN METASTASIS FROM Her2-POSITIVE BREAST CANCER: A COLLABORATIVE STUDY OF NRG AND KROG (NCT01622868). Neuro-Oncology, 2015, 17, v49.2-v49.	0.6	0
227	RTRB-03SHORT DELAY IN INITIATION OF RADIOTHERAPY WITH CONCURRENT CHEMOTHERAPY FOR GLIOBLASTOMA: A SECONDARY ANALYSIS OF NRG ONCOLOGY/RTOG 0525 AND 0825. Neuro-Oncology, 2015, 17, v195.3-v195.	0.6	0
228	OP02ADOLESCENT/YOUNG ADULT MEDULLOBLASTOMA: TIME FOR A CHANGE IN MANAGEMENT STRATEGY. Neuro-Oncology, 2015, 17, viii16.2-viii16.	0.6	0
229	ATCT-09IDH1 R132H MUTATIONS IN NRG ONCOLOGY/RTOG 9802: PHASE III STUDY OF RADIATION THERAPY (RT) ALONE VS RT PLUS PROCARBAZINE, CCNU, AND VINCRISTINE (PCV) IN PATIENTS WITH LOW GRADE GLIOMA (LGG). Neuro-Oncology, 2015, 17, v3.1-v3.	0.6	4
230	Whole-Brain Radiotherapy and Stereotactic Radiosurgery in Brain Metastases: What Is the Evidence?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , e99-e104.	1.8	14
231	Primary Treatment Options for High-Risk/Medically Inoperable Early Stage NSCLC Patients. Clinical Lung Cancer, 2015, 16, 413-430.	1.1	45
232	Response assessment criteria for brain metastases: proposal from the RANO group. Lancet Oncology, The, 2015, 16, e270-e278.	5.1	711
233	ATNT-10DOES VALPROIC ACID IMPROVE SURVIVAL IN GLIOBLASTOMA? A META-ANALYSIS OF RANDOMIZED TRIALS IN NEWLY DIAGNOSED GLIOBLASTOMA. Neuro-Oncology, 2015, 17, v12.2-v12.	0.6	1
234	ATCT-29INVESTIGATING THE EFFECT OF REIRRADIATION OR SYSTEMIC THERAPY IN PATIENTS WITH GBM AFTER TUMOR PROGRESSION: A SECONDARY ANALYSIS OF THE NRG ONCOLOGY/RTOG 0525. Neuro-Oncology, 2015, 17, v8.1-v8.	0.6	0

#	Article	IF	Citations
235	ATCT-08THE IMPACT OF EXTENDED ADJUVANT TEMOZOLOMIDE IN NEWLY-DIAGNOSED GLIOBLASTOMA: A SECONDARY ANALYSIS OF EORTC AND NRG ONCOLOGY/RTOG. Neuro-Oncology, 2015, 17, v2.4-v2.	0.6	3
236	ATCT-27NRG ONCOLOGY/RTOG 0929: A RANDOMIZED PHASE I/II STUDY OF ABT-888IN COMBINATION WITH TEMOZOLOMIDE IN RECURRENT TEMOZOLOMIDE RESISTANT GLIOBLASTOMA. Neuro-Oncology, 2015, 17, v7.3-v7.	0.6	3
237	Bevacizumab Use in Patients With Subtotal Resection of Newly Diagnosed Glioblastoma (GBM): A Secondary Analysis of NRG Oncology/RTOG 0825. International Journal of Radiation Oncology Biology Physics, 2015, 93, S110.	0.4	0
238	Variation over time and interdependence between disease progression and death among patients with glioblastoma on RTOG 0525. Neuro-Oncology, 2015, 17, 999-1006.	0.6	15
239	Society for Neuro-Oncology 2014 annual meeting updates on central nervous system metastases. Neuro-Oncology Practice, 2015, 2, 57-61.	1.0	1
240	ATCT-12RESULTS OF NRG ONCOLOGY/RTOG 9813- A PHASE III RANDOMIZED STUDY OF RADIATION THERAPY (RT) AND TEMOZOLOMIDE (TMZ) VERSUS RT AND NITROSOUREA (NU) THERAPY FOR ANAPLASTIC ASTROCYTOMA (AA). Neuro-Oncology, 2015, 17, v3.4-v3.	0.6	1
241	RTRB-14TREATMENT RECOMMENDATIONS FOR ELDERLY PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA LACK WORLDWIDE CONSENSUS. Neuro-Oncology, 2015, 17, v198.2-v198.	0.6	0
242	Phase 2 Study of Temozolomide-Based Chemoradiation Therapy for High-Risk Low-Grade Gliomas: Preliminary Results of Radiation Therapy Oncology Group 0424. International Journal of Radiation Oncology Biology Physics, 2015, 91, 497-504.	0.4	134
243	Brain Metastasis and Response to Ado-Trastuzumab Emtansine: A Case Report and Literature Review. Clinical Breast Cancer, 2015, 15, e163-e166.	1.1	21
244	Real-Time Pretreatment Review Limits Unacceptable Deviations on a Cooperative Group Radiation Therapy Technique Trial: Quality Assurance Results of RTOG 0933. International Journal of Radiation Oncology Biology Physics, 2015, 91, 564-570.	0.4	27
245	Whole-Brain Radiotherapy for Brain Metastases: Is the Therapeutic Window Enlarging?. , 2015, , 41-56.		0
246	In Regard to Badiyan etÂal. International Journal of Radiation Oncology Biology Physics, 2015, 91, 453-454.	0.4	3
247	Should we irradiate a brain tumor in a patient with parkinsonism? A case report and literature review. Practical Radiation Oncology, 2015, 5, e327-e335.	1.1	2
248	Atypical meningioma: Randomized trials are required to resolve contradictory retrospective results regarding the role of adjuvant radiotherapy. Journal of Cancer Research and Therapeutics, 2015, 11, 59.	0.3	44
249	The controversy surrounding the use of whole-brain radiotherapy in brain metastases patients. Neuro-Oncology, 2015, 17, 919-923.	0.6	23
250	Veliparib in combination with whole brain radiation therapy in patients with brain metastases: results of a phase 1 study. Journal of Neuro-Oncology, 2015, 122, 409-417.	1.4	88
251	Phase 2 trial of dasatinib in target-selected patients with recurrent glioblastoma (RTOG 0627). Neuro-Oncology, 2015, 17, 992-998.	0.6	116
252	Outcome and prognostic factors for children with supratentorial primitive neuroectodermal tumors treated with carboplatin during radiotherapy: A report from the Children's Oncology Group. Pediatric Blood and Cancer, 2015, 62, 776-783.	0.8	58

#	Article	IF	Citations
253	Phase II trial of pre-irradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: long term results of RTOG BR0131. Journal of Neuro-Oncology, 2015, 124, 413-420.	1.4	27
254	Reply to M.C. Chamberlain. Journal of Clinical Oncology, 2015, 33, 1986-1986.	0.8	0
255	Comparison of Overall Survival for Esophageal Cancer Patients Treated With Neoadjuvant Proton or Photon Chemoradiation: A Multi-institutional Analysis. International Journal of Radiation Oncology Biology Physics, 2015, 93, S13-S14.	0.4	0
256	Cost-Effectiveness of Prophylactic Cranial Irradiation With Hippocampal Avoidance in Limited Stage Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2015, 93, S92.	0.4	4
257	Clinical Outcomes for Esophageal Cancer Patients Treated With Intensity Modulated Radiation Therapy Compared to 3-D Conformal Radiation Therapy: An Analysis of the National Cancer Data Base. International Journal of Radiation Oncology Biology Physics, 2015, 93, E165-E166.	0.4	0
258	Fact or Fiction: Proton Beam Therapy is Primarily for Patients With Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2015, 93, E353-E354.	0.4	0
259	Volumetric Analysis of the Hippocampus in Long Term (âˆ¼1 year) Survivors of Whole Brain-Radiation Therapy for Brain Metastasis. International Journal of Radiation Oncology Biology Physics, 2015, 93, E69.	0.4	0
260	Minimal Early Increase in Contrast Enhancement After Chemoradiation Therapy for Glioblastoma Predicts Worse Overall and Progression Free Survival. International Journal of Radiation Oncology Biology Physics, 2015, 93, E106-E107.	0.4	0
261	Results of NRG oncology/RTOG 9813: A phase III randomized study of radiation therapy (RT) and temozolomide (TMZ) versus RT and nitrosourea (NU) therapy for anaplastic astrocytoma (AA).. Journal of Clinical Oncology, 2015, 33, 2002-2002.	0.8	6
262	Results of a randomized, global, multi-center study of whole-brain radiation therapy (WBRT) plus veliparib or placebo in patients (pts) with brain metastases (BM) from non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2015, 33, 2021-2021.	0.8	7
263	Strategies for preservation of memory function in patients with brain metastases. Chinese Clinical Oncology, 2015, 4, 24.	0.4	22
264	Management of solitary and multiple brain metastases from breast cancer. Indian Journal of Medical and Paediatric Oncology, 2015, 36, 87-93.	0.1	18
265	Stereotactic Radiosurgery for Glioblastoma. Cureus, 2015, 7, e413.	0.2	32
266	Brain metastases: the changing landscape. Oncology, 2015, 29, 257-60.	0.4	1
267	Radiation-induced brain damage, impact of Michael Robbinsâ€™ work and the need for predictive biomarkers. International Journal of Radiation Biology, 2014, 90, 742-752.	1.0	17
268	Prophylactic cranial irradiation: recent outcomes and innovations. CNS Oncology, 2014, 3, 219-230.	1.2	13
269	Recent Updates in the Treatment of Glioblastoma: Introduction. Seminars in Oncology, 2014, 41, S1-S3.	0.8	6
270	Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02. Neuro-Oncology, 2014, 16, 567-578.	0.6	140

#	Article	IF	Citations
271	Bevacizumab for Newly Diagnosed Glioblastoma. New England Journal of Medicine, 2014, 370, 2048-2049.	13.9	98
272	Preservation of Memory With Conformal Avoidance of the Hippocampal Neural Stem-Cell Compartment During Whole-Brain Radiotherapy for Brain Metastases (RTOG 0933): A Phase II Multi-Institutional Trial. Journal of Clinical Oncology, 2014, 32, 3810-3816.	0.8	894
273	Markov Model and Cost-Effectiveness Analysis of Bevacizumab in HER2-Negative Metastatic Breast Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2014, 37, 480-485.	0.6	16
274	Reirradiation for Locoregionally Recurrent Lung Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2014, 37, 70-76.	0.6	37
275	It Is Time to Reevaluate the Management of Patients With Brain Metastases. Neurosurgery, 2014, 75, 1-9.	0.6	21
276	Single institution experience treating 104 vestibular schwannomas with fractionated stereotactic radiation therapy or stereotactic radiosurgery. Journal of Neuro-Oncology, 2014, 116, 187-193.	1.4	62
277	A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma. New England Journal of Medicine, 2014, 370, 699-708.	13.9	2,279
278	Potential of glyburide to reduce intracerebral edema in brain metastases. Expert Review of Neurotherapeutics, 2014, 14, 379-388.	1.4	8
279	Effect of the Addition of Chemotherapy to Radiotherapy on Cognitive Function in Patients With Low-Grade Glioma: Secondary Analysis of RTOG 98-02. Journal of Clinical Oncology, 2014, 32, 535-541.	0.8	97
280	Reply to M.C. Chamberlain. Journal of Clinical Oncology, 2014, 32, 1634-1635.	0.8	2
281	Secondary Analysis of RTOG 9508, a Phase 3 Randomized Trial of Whole-Brain Radiation Therapy Versus WBRT Plus Stereotactic Radiosurgery in Patients With 1-3 Brain Metastases; Poststratified by the Graded Prognostic Assessment (GPA). International Journal of Radiation Oncology Biology Physics, 2014, 90, 526-531.	0.4	155
282	Strategies to Prevent Brain Metastasis in High-Risk Nonâ€"Small-Cell Lung Cancer: Lessons Learned From a Randomized Study of Maintenance Temozolomide Versus Observation. Clinical Lung Cancer, 2014, 15, 433-440.	1.1	16
283	Large Tumor Size Increases the Risk of Developing Symptomatic Pleural Effusions Following Stereotactic Body Radiation Therapy for Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2014, 90, S664.	0.4	0
284	Breath-Hold Intensity Modulated Proton Therapy (BH-IMPT) for Lung SBRT: Feasibility Study. International Journal of Radiation Oncology Biology Physics, 2014, 90, S142.	0.4	4
285	Comparison of Coronary Vessel Contouring Using Non-Contrast Cardiac Gated CT Versus CT Angiogram. International Journal of Radiation Oncology Biology Physics, 2014, 90, S263.	0.4	0
286	Benefit From Procarbazine, Lomustine, and Vincristine in Oligodendroglial Tumors Is Associated With Mutation ofIDH. Journal of Clinical Oncology, 2014, 32, 783-790.	0.8	356
287	Real-Time Pretreatment Review Limits Unacceptable Deviations: Quality Assurance (QA) Results of RTOG 0933. International Journal of Radiation Oncology Biology Physics, 2014, 90, S318.	0.4	0
288	Application of a Survival-Predicting Nomogram Based Primarily on Whole-Brain Radiation Therapyâ€"Treated Patients With Brain Metastases Yields Significant Underestimates for Radiosurgery-Treated Patients. International Journal of Radiation Oncology Biology Physics, 2014, 90, S911.	0.4	0

#	Article	IF	Citations
289	High prevalence of hepatitis B non-immunity in paediatric non-alcoholic fatty liver disease patients. Digestive and Liver Disease, 2014, 46, 760-761.	0.4	4
290	Brain metastasis and treatment. F1000prime Reports, 2014, 6, 114.	5.9	44
291	AT-13 * R9802: PHASE III STUDY OF RADIATION THERAPY (RT) WITH OR WITHOUT PROCARBAZINE, CCNU, AND VINCRISTINE (PCV) IN LOW-GRADE QLIOMA: RESULTS BY HISTOLOGIC TYPE. Neuro-Oncology, 2014, 16, v11-v11.	0.6	7
292	Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and vincristine (PCV) in low-grade glioma: RTOG 9802 with Alliance, ECOG, and SWOG.. Journal of Clinical Oncology, 2014, 32, 2000-2000.	0.8	35
293	RTOG 1119: Phase II randomized study of whole brain radiotherapy with concurrent lapatinib in patients with brain metastasis from HER2-positive breast cancerâ€"A collaborative study of RTOG and KROG (NCT01622868).. Journal of Clinical Oncology, 2014, 32, TPS664-TPS664.	0.8	1
294	Phase II study of arsenic trioxide and temozolomide in combination with radiation therapy in patients with malignant gliomas.. Journal of Clinical Oncology, 2014, 32, 2072-2072.	0.8	0
295	Is proton beam therapy better than standard radiation therapy? The available evidence points to benefits of proton beam therapy. Clinical Advances in Hematology and Oncology, 2014, 12, 861-4.	0.3	2
296	The effect of tumor subtype on the time from primary diagnosis to development of brain metastases and survival in patients with breast cancer. Journal of Neuro-Oncology, 2013, 112, 467-472.	1.4	137
297	RTOG 0211: A Phase 1/2 Study of Radiation Therapy With Concurrent Gefitinib for Newly Diagnosed Glioblastoma Patients. International Journal of Radiation Oncology Biology Physics, 2013, 85, 1206-1211.	0.4	137
298	Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial. Neuro-Oncology, 2013, 15, 1429-1437.	0.6	746
299	RTOG 0913: A Phase 1 Study of Daily Everolimus (RAD001) in Combination With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma. International Journal of Radiation Oncology Biology Physics, 2013, 86, 880-884.	0.4	55
300	New validated prognostic models and prognostic calculators in patients with low-grade gliomas diagnosed by central pathology review: a pooled analysis of EORTC/RTOG/NCCTG phase III clinical trials. Neuro-Oncology, 2013, 15, 1568-1579.	0.6	88
301	Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial. Journal of Clinical Oncology, 2013, 31, 4085-4091.	0.8	820
302	Phase III Trial of Chemoradiotherapy for Anaplastic Oligodendroglioma: Long-Term Results of RTOG 9402. Journal of Clinical Oncology, 2013, 31, 337-343.	0.8	968
303	Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group. Lancet Oncology, The, 2013, 14, e396-e406.	5.1	116
304	Challenges relating to solid tumour brain metastases in clinical trials, part 2: neurocognitive, neurological, and quality-of-life outcomes. A report from the RANO group. Lancet Oncology, The, 2013, 14, e407-e416.	5.1	119
305	Dose-Limiting Toxicity After Hypofractionated Dose-Escalated Radiotherapy in Nonâ€"Small-Cell Lung Cancer. Journal of Clinical Oncology, 2013, 31, 4343-4348.	0.8	132
306	A phase II study of conventional radiation therapy and thalidomide for supratentorial, newly-diagnosed glioblastoma (RTOG 9806). Journal of Neuro-Oncology, 2013, 111, 33-39.	1.4	15

#	Article	IF	Citations
307	Predictive Factors for Brain Metastases and Relapse and Prognostic Factors for Survival in Stage III-IV Non-Small Cell Lung Cancer (NSCLC). International Journal of Radiation Oncology Biology Physics, 2013, 87, S525.	0.4	1
308	In Regard to Sperduto et al. International Journal of Radiation Oncology Biology Physics, 2013, 86, 809-810.	0.4	9
309	Cilengitide Inhibits Proliferation and Shows Combined Effects With Radiation in Breast Cancer Cell Lines. International Journal of Radiation Oncology Biology Physics, 2013, 87, S658.	0.4	0
310	Hippocampal Dosimetry Predicts Neurocognitive Function Impairment After Fractionated Stereotactic Radiotherapy for Benign or Low-Grade Adult Brain Tumors. International Journal of Radiation Oncology Biology Physics, 2013, 85, 348-354.	0.4	303
311	A Phase 3 Trial of Whole Brain Radiation Therapy and Stereotactic Radiosurgery Alone Versus WBRT and SRS With Temozolomide or Erlotinib for Non-Small Cell Lung Cancer and 1 to 3 Brain Metastases: Radiation Therapy Oncology Group 0320. International Journal of Radiation Oncology Biology Physics, 2013, 85, 1312-1318.	0.4	254
312	Credentialing in Hippocampal (HC) Sparing Techniques for RTOG 0933: Quality Assurance (QA) Report. International Journal of Radiation Oncology Biology Physics, 2013, 87, S576.	0.4	1
313	Predictive value of tumor recurrence using urinary vascular endothelial factor levels in patients receiving radiation therapy for Glioblastoma Multiforme (GBM). Biomarker Research, 2013, 1, 29.	2.8	3
314	Pseudoprogression after glioma therapy: a comprehensive review. Expert Review of Neurotherapeutics, 2013, 13, 389-403.	1.4	92
315	Molecular Profiling in Nonâ€"Small Cell Lung Cancer: A Step Toward Personalized Medicine. Archives of Pathology and Laboratory Medicine, 2013, 137, 481-491.	1.2	52
316	Opportunities and Challenges in the Era of Molecularly Targeted Agents and Radiation Therapy. Journal of the National Cancer Institute, 2013, 105, 686-693.	3.0	40
317	American College of Radiology (ACR) and American Society for Radiation Oncology (ASTRO) Practice Guideline for the Performance of Stereotactic Radiosurgery (SRS). American Journal of Clinical Oncology: Cancer Clinical Trials, 2013, 36, 310-315.	0.6	91
318	Chemoradiation for Definitive, Preoperative, or Postoperative Therapy of Locally Advanced Non-Small Cell Lung Cancer. Cancer Journal (Sudbury, Mass), 2013, 19, 222-230.	1.0	9
319	Net Clinical Benefit Analysis of Radiation Therapy Oncology Group 0525: A Phase III Trial Comparing Conventional Adjuvant Temozolomide With Dose-Intensive Temozolomide in Patients With Newly Diagnosed Glioblastoma. Journal of Clinical Oncology, 2013, 31, 4076-4084.	0.8	110
320	Using Intensity-Modulated Radiotherapy to Spare the Kidney in a Patient with Seminoma and a Solitary Kidney: A Case Report. Tumori, 2013, 99, e38-e42.	0.6	5
321	Neurocognitive function (NCF) outcomes in patients with glioblastoma (GBM) enrolled in RTOG 0825.. Journal of Clinical Oncology, 2013, 31, 2004-2004.	0.8	18
322	A phase II study of a temozolomide-based chemoradiotherapy regimen for high-risk low-grade gliomas: Preliminary results of RTOG 0424.. Journal of Clinical Oncology, 2013, 31, 2008-2008.	0.8	21
323	RTOG 0825: Phase III double-blind placebo-controlled trial evaluating bevacizumab (Bev) in patients (Pts) with newly diagnosed glioblastoma (GBM).. Journal of Clinical Oncology, 2013, 31, 1-1.	0.8	52
324	Molecular predictors of outcome and response to bevacizumab (BEV) based on analysis of RTOG 0825, a phase III trial comparing chemoradiation (CRT) with and without BEV in patients with newly diagnosed glioblastoma (GBM).. Journal of Clinical Oncology, 2013, 31, LBA2010-LBA2010.	0.8	18

#	Article	IF	Citations
325	Orbital metastasis of pituitary growth hormone secreting carcinoma causing lateral gaze palsy. , 2013, 4, 59.		7
326	Abstract A110: EGFRvIII expression is associated with shorter progression-free and overall survival in glioblastoma patients treated with standard-of-care temozolomide and radiation: A report from the RTOG-0525 trial.. , 2013, , .		0
327	Using intensity-modulated radiotherapy to spare the kidney in a patient with seminoma and a solitary kidney: a case report. Tumori, 2013, 99, e38-42.	0.6	2
328	Brain metastases. Current Opinion in Supportive and Palliative Care, 2012, 6, 85-90.	0.5	14
329	Cognitive function testing in adult brain tumor trials: lessons from a comprehensive review. Expert Review of Anticancer Therapy, 2012, 12, 655-667.	1.1	14
330	Randomized Phase III Study of Thoracic Radiation in Combination With Paclitaxel and Carboplatin With or Without Thalidomide in Patients With Stage III Nonâ€"Small-Cell Lung Cancer: The ECOG 3598 Study. Journal of Clinical Oncology, 2012, 30, 616-622.	0.8	75
331	Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02. Neuro-Oncology, 2012, 14, 1511-1518.	0.6	95
332	Randomized Trial of Radiation Therapy Plus Procarbazine, Lomustine, and Vincristine Chemotherapy for Supratentorial Adult Low-Grade Glioma: Initial Results of RTOG 9802. Journal of Clinical Oncology, 2012, 30, 3065-3070.	0.8	301
333	Reply to M.C. Chamberlain et al. Journal of Clinical Oncology, 2012, 30, 3316-3317.	0.8	2
334	Integrated phase II/III clinical trials in oncology: A case study. Clinical Trials, 2012, 9, 741-747.	0.7	7
335	In regards to Kirby et al . â€œPhysics strategies for sparing neural stem cells during whole-brain radiation treatments,â€•[Med. Phys. 38, 5338 (2011)]. Medical Physics, 2012, 39, 1677-1678.	1.6	0
336	Differential Sensitivity of Glioma- versus Lung Cancerâ€"Specific EGFR Mutations to EGFR Kinase Inhibitors. Cancer Discovery, 2012, 2, 458-471.	7.7	304
337	A nomogram for individualized estimation of survival among patients with brain metastasis. Neuro-Oncology, 2012, 14, 910-918.	0.6	126
338	Effect of Tumor Subtype on Survival and the Graded Prognostic Assessment for Patients With Breast Cancer and Brain Metastases. International Journal of Radiation Oncology Biology Physics, 2012, 82, 2111-2117.	0.4	321
339	Hippocampal Dosimetry Predicts Neurocognitive Function Impairment After Fractionated Stereotactic Radiotherapy for Benign or Low-Grade Adult Brain Tumors. International Journal of Radiation Oncology Biology Physics, 2012, 83, e487-e493.	0.4	168
340	In Regard to Yamamoto et al. International Journal of Radiation Oncology Biology Physics, 2012, 84, 875-876.	0.4	3
341	Phase I Safety and Pharmacokinetic (PK) Study of Veliparib in Combination With Whole Brain Radiation Therapy (WBRT) in Patients (pts) With Brain Metastases. International Journal of Radiation Oncology Biology Physics, 2012, 84, S269-S270.	0.4	8
342	The Effect of Tumor Subtype on the Time From Primary Diagnosis to Development of Brain Metastases and Survival in Women With Breast Cancer. International Journal of Radiation Oncology Biology Physics, 2012, 84, S142.	0.4	0

#	Article	IF	Citations
343	Summary Report on the Graded Prognostic Assessment: An Accurate and Facile Diagnosis-Specific Tool to Estimate Survival for Patients With Brain Metastases. Journal of Clinical Oncology, 2012, 30, 419-425.	0.8	1,205
344	Brain Metastases Research 1990â€“2010: Pattern of Citation and Systematic Review of Highly Cited Articles. Scientific World Journal, The, 2012, 2012, 1-9.	0.8	7
345	Outcome of Children With Metastatic Medulloblastoma Treated With Carboplatin During Craniospinal Radiotherapy: A Children's Oncology Group Phase I/II Study. Journal of Clinical Oncology, 2012, 30, 2648-2653.	0.8	166
346	Intracranial relapse rates and patterns, and survival trends following post-resection cavity radiosurgery for patients with single intracranial metastases. Journal of Neuro-Oncology, 2012, 108, 141-146.	1.4	26
347	Cilengitide in patients with recurrent glioblastoma: the results of NABTC 03-02, a phase II trial with measures of treatment delivery. Journal of Neuro-Oncology, 2012, 106, 147-153.	1.4	114
348	Brain metastases: pathobiology and emerging targeted therapies. Acta Neuropathologica, 2012, 123, 205-222.	3.9	163
349	Stereotactic Irradiation. , 2012, , 331-343.		2
350	Abstract 736: RTOG 0320:A phase III trial comparing whole brain radiation therapy (WBRT) and stereotactic radiosurgery (SRS) alone versus WBRT with temozolomide (TMZ) or erlotinib for non-small cell lung cancer (NSCLC) and 1-3 brain metastases. Cancer Research, 2012, 72, 736-736.	0.4	4
351	Estimated radiation pneumonitis risk after photon versus proton therapy alone or combined with chemotherapy for lung cancer. Acta OncolÃ³gica, 2011, 50, 772-776.	0.8	25
352	An LXR Agonist Promotes Glioblastoma Cell Death through Inhibition of an EGFR/AKT/SREBP-1/LDLRâ€“Dependent Pathway. Cancer Discovery, 2011, 1, 442-456.	7.7	346
353	Advances in translational research provide a rationale for clinical re-evaluation of high-dose radiotherapy for glioblastoma. Medical Hypotheses, 2011, 76, 410-413.	0.8	15
354	In response to â€œThe distribution of brain metastases in the perihippocampal region (Regarding Gondi et) Tj ETQq0 0 0 rgBT /Overlock	0.3	3
355	Dosimetric comparison of left-sided whole breast irradiation with 3DCRT, forward-planned IMRT, inverse-planned IMRT, helical tomotherapy, and topotherapy. Radiotherapy and Oncology, 2011, 100, 241-246.	0.3	148
356	Validation and Simplification of the Radiation Therapy Oncology Group Recursive Partitioning Analysis Classification for Glioblastoma. International Journal of Radiation Oncology Biology Physics, 2011, 81, 623-630.	0.4	203
357	A Phase I Trial of Tipifarnib With Radiation Therapy, With and Without Temozolomide, for Patients With Newly Diagnosed Glioblastoma. International Journal of Radiation Oncology Biology Physics, 2011, 81, 1422-1427.	0.4	28
358	Reply to Drs. Mulvenna and Holt. International Journal of Radiation Oncology Biology Physics, 2011, 81, 1194-1195.	0.4	0
359	Predicting Neurocognitive Function (NCF) Impairment following Fractionated Stereotactic Radiotherapy (FSRT) for Benign or Low-Grade Adult Brain Tumors. International Journal of Radiation Oncology Biology Physics, 2011, 81, S285-S286.	0.4	1
360	RTOG 0525: Exploratory Subset Analysis from a Randomized Phase III Trial Comparing Standard (std) Adjuvant Temozolomide (TMZ) with a Dose-dense (dd) Schedule for Glioblastoma (GBM). International Journal of Radiation Oncology Biology Physics, 2011, 81, S128-S129.	0.4	3

#	Article	IF	Citations
361	Phase II Trial of Temozolomide (TMZ), Motexafin Gadolinium (MGd), and 60 Gy Fractionated Radiation (RT) for Newly Diagnosed Supratentorial Glioblastoma (GBM): Results of RTOG 0513. International Journal of Radiation Oncology Biology Physics, 2011, 81, S129-S130.	0.4	2
362	Predictive Value of Tumor Recurrence using Urinary Vascular Endothelial Growth Factor Levels in Patients Receiving Radiation Therapy for Glioblastoma. International Journal of Radiation Oncology Biology Physics, 2011, 81, S181.	0.4	0
363	Crimean-Congo haemorrhagic fever in India. Lancet, The, 2011, 378, 372.	6.3	58
364	Combined Modality Approaches in the Management of Adult Glioblastoma. Frontiers in Oncology, 2011, 1, 36.	1.3	8
365	Stereotactic Body Radiation Therapy in Nonâ€"Small-Cell Lung Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2011, 34, 432-441.	0.6	13
366	Temozolomide-induced severe myelosuppression. Anti-Cancer Drugs, 2011, 22, 104-110.	0.7	19
367	A Comparison of Helical Tomotherapy to Circular Collimator-Based Linear-Accelerator Radiosurgery for the Treatment of Brain Metastases. American Journal of Clinical Oncology: Cancer Clinical Trials, 2011, 34, 388-394.	0.6	17
368	Early toxicity predicts long-term survival in high-grade glioma. British Journal of Cancer, 2011, 104, 1365-1371.	2.9	35
369	Current practices of driving restriction implementation for patients with brain tumors. Journal of Neuro-Oncology, 2011, 103, 641-647.	1.4	18
370	Age as an independent prognostic factor in patients with glioblastoma: a radiation therapy oncology group and American College of Surgeons National Cancer Data Base comparison. Journal of Neuro-Oncology, 2011, 104, 351-356.	1.4	40
371	Safety and feasibility of motexafin gadolinium administration with whole brain radiation therapy and stereotactic radiosurgery boost in the treatment of â‰¥6 brain metastases: a multi-institutional phase II trial. Journal of Neuro-Oncology, 2011, 105, 301-308.	1.4	16
372	Presentation, patterns of care, and survival in patients with brain metastases. Cancer, 2011, 117, 2505-2512.	2.0	163
373	In Response to Dr. Knisely and Colleagues. International Journal of Radiation Oncology Biology Physics, 2011, 79, 958.	0.4	1
374	Intensity-Modulated Radiotherapy Might Increase Pneumonitis Risk Relative to Three-Dimensional Conformal Radiotherapy in Patients Receiving Combined Chemotherapy and Radiotherapy: A Modeling Study of Dose Dumping. International Journal of Radiation Oncology Biology Physics, 2011, 80, 893-899.	0.4	32
375	Pro: Lung Cancer in 2011: A Time for Optimism and Investment in New Approaches and Technologies with a Commitment to Produce Evidence-Based Data. American Journal of Respiratory and Critical Care Medicine, 2011, 184, 1231-1234.	2.5	0
376	Leptomeningeal Metastasis: Challenges in Diagnosis and Treatment. Current Cancer Therapy Reviews, 2011, 7, 319-327.	0.2	108
377	Phase II Study of Aflibercept in Recurrent Malignant Glioma: A North American Brain Tumor Consortium Study. Journal of Clinical Oncology, 2011, 29, 2689-2695.	0.8	204
378	Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma?. Neuro-Oncology, 2011, 13, 1118-1124.	0.6	100

#	Article	IF	Citations
379	Myeloid Biomarkers Associated with Glioblastoma Response to Anti-VEGF Therapy with Aflibercept. Clinical Cancer Research, 2011, 17, 4872-4881.	3.2	59
380	Advances in Radiation Oncology of Lung Cancer. Medical Radiology, 2011, , 725-733.	0.0	0
381	Role of isocitrate dehydrogenase in glioma. Expert Review of Neurotherapeutics, 2011, 11, 1399-1409.	1.4	15
382	The Dandelion Effect: Treat the Whole Lawn or Weed Selectively?. Journal of Clinical Oncology, 2011, 29, 121-124.	0.8	30
383	It Is Time to Include Patients With Brain Tumors in Phase I Trials in Oncology. Journal of Clinical Oncology, 2011, 29, 3211-3213.	0.8	21
384	Clinical trial end points for high-grade glioma: the evolving landscape. Neuro-Oncology, 2011, 13, 353-361.	0.6	105
385	Prognostic value of H-MLH1 after adjusting for RPA class in GBM patients. Frontiers in Bioscience - Elite, 2011, E3, 1182-1191.	0.9	2
386	Incidence of rib fractures after stereotactic body radiotherapy for peripheral lung lesions: clinical experience and dose response estimation. Journal of Radiosurgery and SBRT, 2011, 1, 155-161.	0.2	0
387	Prognostic factors for complete obliteration of arteriovenous malformations treated with LINAC-based stereotactic radiosurgery. Journal of Radiosurgery and SBRT, 2011, 1, 203-211.	0.2	0
388	Initial clinical experience with stereotactic lung radiotherapy, based on a biological model-driven prescription method. Journal of Radiosurgery and SBRT, 2011, 1, 221-229.	0.2	0
389	Novel insights into the management of brain metastases. Current Opinion in Neurology, 2010, 23, 556-562.	1.8	18
390	Cognition and Quality of Life After Chemotherapy Plus Radiotherapy (RT) vs. RT for Pure and Mixed Anaplastic Oligodendrogliomas: Radiation Therapy Oncology Group Trial 9402. International Journal of Radiation Oncology Biology Physics, 2010, 77, 662-669.	0.4	47
391	On the Use of Hyperpolarized Helium MRI for Conformal Avoidance Lung Radiotherapy. Medical Dosimetry, 2010, 35, 297-303.	0.4	34
392	The role of retreatment in the management of recurrent/progressive brain metastases: a systematic review and evidence-based clinical practice guideline. Journal of Neuro-Oncology, 2010, 96, 85-96.	1.4	125
393	The role of prophylactic anticonvulsants in the management of brain metastases: a systematic review and evidence-based clinical practice guideline. Journal of Neuro-Oncology, 2010, 96, 97-102.	1.4	126
394	The role of steroids in the management of brain metastases: a systematic review and evidence-based clinical practice guideline. Journal of Neuro-Oncology, 2010, 96, 103-114.	1.4	283
395	The role of emerging and investigational therapies for metastatic brain tumors: a systematic review and evidence-based clinical practice guideline of selected topics. Journal of Neuro-Oncology, 2010, 96, 115-142.	1.4	48
396	The role of whole brain radiation therapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. Journal of Neuro-Oncology, 2010, 96, 17-32.	1.4	277

#	Article	IF	Citations
397	The role of surgical resection in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. Journal of Neuro-Oncology, 2010, 96, 33-43.	1.4	361
398	The role of chemotherapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. Journal of Neuro-Oncology, 2010, 96, 71-83.	1.4	141
399	The role of stereotactic radiosurgery in the management of patients with newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. Journal of Neuro-Oncology, 2010, 96, 45-68.	1.4	446
400	Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma. Journal of Neuro-Oncology, 2010, 96, 211-217.	1.4	163
401	Fractionated radiotherapy for intracranial meningiomas. Journal of Neuro-Oncology, 2010, 99, 349-356.	1.4	22
402	Opportunities for clinical research in meningioma. Journal of Neuro-Oncology, 2010, 99, 417-422.	1.4	23
403	Angiogenic Blockade and Radiotherapy in Hepatocellular Carcinoma. International Journal of Radiation Oncology Biology Physics, 2010, 78, 188-193.	0.4	46
404	Diagnosis-Specific Prognostic Factors, Indexes, and Treatment Outcomes for Patients With Newly Diagnosed Brain Metastases: A Multi-Institutional Analysis of 4,259 Patients. International Journal of Radiation Oncology Biology Physics, 2010, 77, 655-661.	0.4	873
405	American Society for Therapeutic Radiology and Oncology (ASTRO) and American College of Radiology (ACR) Practice Guideline for the Performance of Stereotactic Body Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2010, 76, 326-332.	0.4	473
406	Hippocampal-Sparing Whole-Brain Radiotherapy: A â€œHow-Toâ€•Technique Using Helical Tomotherapy and Linear Acceleratorâ€"Based Intensity-Modulated Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2010, 78, 1244-1252.	0.4	305
407	Treatment-Related Pneumonitis and Acute Esophagitis in Non-Small-Cell Lung Cancer Patients Treated With Chemotherapy and Helical Tomotherapy: In Regard to Song etÂal.. International Journal of Radiation Oncology Biology Physics, 2010, 78, 1281.	0.4	0
408	Interim Results of a Phase I Risk-Stratified Dose Escalation Study using Hypofractionated Helical Tomotherapy for Non-small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2010, 78, S107-S108.	0.4	1
409	PROOF OF PRINCIPLE OF OCULAR SPARING IN DOGS WITH SINONASAL TUMORS TREATED WITH INTENSITY-MODULATED RADIATION THERAPY. Veterinary Radiology and Ultrasound, 2010, 51, 561-570.	0.4	66
410	Brain Metastases. Medical Radiology, 2010, , 209-223.	0.0	0
411	A multigene predictor of outcome in glioblastoma. Neuro-Oncology, 2010, 12, 49-57.	0.6	334
412	Current Treatment Strategies for Brain Metastasis and Complications From Therapeutic Techniques. American Journal of Clinical Oncology: Cancer Clinical Trials, 2010, 33, 398-407.	0.6	65
413	A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas. Neuro-Oncology, 2010, 12, 87-94.	0.6	46
414	Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02). Neuro-Oncology, 2010, 12, 855-861.	0.6	184

#	Article	IF	Citations
415	Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma. Neuro-Oncology, 2010, 12, 871-881.	0.6	407
416	A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. Neuro-Oncology, 2010, 12, 95-103.	0.6	252
417	Current Therapeutic Paradigms in Glioblastoma. Reviews on Recent Clinical Trials, 2010, 5, 14-27.	0.4	64
418	Gangliogliomasâ€"what is the appropriate management strategy?. Nature Reviews Neurology, 2010, 6, 190-191.	4.9	3
419	Radiographic Pneumonitis Patterns and Low Pulmonary Toxicity After Helical Tomotherapy. American Journal of Roentgenology, 2010, 194, W459-W459.	1.0	5
420	Simultaneously Integrated Boost to Multiple Brain Metastases during Whole Brain Radiation Therapy-Hippocampal Avoidance. Radiosurgery, 2010, , 247-257.	0.1	1
421	Estimated risk of perihippocampal disease progression after hippocampal avoidance during whole-brain radiotherapy: Safety profile for RTOG 0933. Radiotherapy and Oncology, 2010, 95, 327-331.	0.3	166
422	Why avoid the hippocampus? A comprehensive review. Radiotherapy and Oncology, 2010, 97, 370-376.	0.3	313
423	Short Delay in Initiation of Radiotherapy May Not Affect Outcome of Patients With Glioblastoma: A Secondary Analysis From the Radiation Therapy Oncology Group Database. Journal of Clinical Oncology, 2009, 27, 733-739.	0.8	107
424	Motexafin gadolinium: a novel radiosensitizer for brain tumors. Expert Opinion on Pharmacotherapy, 2009, 10, 2171-2180.	0.9	15
425	Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131. Neuro-Oncology, 2009, 11, 167-175.	0.6	55
426	The Impact of Hybrid PET-CT Scan on Overall Oncologic Management, with a Focus on Radiotherapy Planning: A Prospective, Blinded Study. Technology in Cancer Research and Treatment, 2009, 8, 149-158.	0.8	31
427	EGFR Signaling Through an Akt-SREBP-1â€"Dependent, Rapamycin-Resistant Pathway Sensitizes Glioblastomas to Antilipogenic Therapy. Science Signaling, 2009, 2, ra82.	1.6	282
428	On the Estimation of the Location of the Hippocampus in the Context of Hippocampal Avoidance Whole Brain Radiotherapy Treatment Planning. Technology in Cancer Research and Treatment, 2009, 8, 425-432.	0.8	12
429	Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf	0.6	130
430	A Phase II Study of Preradiotherapy Chemotherapy Followed by Hyperfractionated Radiotherapy for Newly Diagnosed High-Risk Medulloblastoma/Primitive Neuroectodermal Tumor: A Report From the Children's Oncology Group (CCG 9931). International Journal of Radiation Oncology Biology Physics, 2009, 74, 1006-1011.	0.4	47
431	A North American brain tumor consortium phase II study of poly-ICLC for adult patients with recurrent anaplastic gliomas. Journal of Neuro-Oncology, 2009, 91, 183-189.	1.4	68
432	Health related quality of life and cognitive status in patients with glioblastoma multiforme receiving escalating doses of conformal three dimensional radiation on RTOG 98-03. Journal of Neuro-Oncology, 2009, 95, 247-257.	1.4	40

#	Article	IF	Citations
433	Prognostic indices for brain metastases â€“ usefulness and challenges. Radiation Oncology, 2009, 4, 10.	1.2	91
434	Phase I Three-Dimensional Conformal Radiation Dose Escalation Study in Newly Diagnosed Glioblastoma: Radiation Therapy Oncology Group Trial 98-03. International Journal of Radiation Oncology Biology Physics, 2009, 73, 699-708.	0.4	91
435	Motexafin Gadolinium Combined With Prompt Whole Brain Radiotherapy Prolongs Time to Neurologic Progression in Nonâ€“Small-Cell Lung Cancer Patients With Brain Metastases: Results of a Phase III Trial. International Journal of Radiation Oncology Biology Physics, 2009, 73, 1069-1076.	0.4	161
436	Radiation Techniques in Neuro-Oncology. Neurotherapeutics, 2009, 6, 487-499.	2.1	13
437	Combined Radio- and Chemotherapy of Brain Tumours in Adult Patients. Clinical Oncology, 2009, 21, 515-524.	0.6	30
438	A Comprehensive Assessment by Tumor Site of Patient Setup Using Daily MVCT Imaging From More Than 3,800 Helical Tomotherapy Treatments. International Journal of Radiation Oncology Biology Physics, 2009, 73, 1260-1269.	0.4	90
439	Commissioning and Quality Assurance of RapidArc Radiotherapy Delivery System: In Regard to Ling et al. (Int J Radiat Oncol Biol Phys 2008;72;575â€“581): Absence of Data Does Not Constitute Proof; The Proof is in Tasting the Pudding. International Journal of Radiation Oncology Biology Physics, 2009, 75, 4-6.	0.4	18
440	Dose-Escalated High-Precision Radiotherapy: a Method to Overcome Variations in Biology and Radiosensitivity Limiting the Success of Conventional Approaches?. Medical Radiology, 2009, , 335-346.	0.0	0
441	Brain metastases. , 2008, , 170-186.		2
442	Radiation therapy of pathologically confirmed newly diagnosed glioblastoma in adults. Journal of Neuro-Oncology, 2008, 89, 313-337.	1.4	33
443	Effect of dalteparin and radiation on survival and thromboembolic events in glioblastoma multiforme: a phase II ECOG trial. Cancer Chemotherapy and Pharmacology, 2008, 62, 227-233.	1.1	54
444	A phase I study of gemcitabine plus palliative radiation therapy for advanced lung cancer. Cancer Chemotherapy and Pharmacology, 2008, 63, 175-179.	1.1	7
445	The prognostic value of nestin expression in newly diagnosed glioblastoma: Report from the Radiation Therapy Oncology Group. Radiation Oncology, 2008, 3, 32.	1.2	44
446	The Prognostic Value of Nestin Expression in Newly Diagnosed GBM: Report from the RTOG. International Journal of Radiation Oncology Biology Physics, 2008, 72, S206.	0.4	0
447	In Reply to Drs. Nieder and Molls. International Journal of Radiation Oncology Biology Physics, 2008, 72, 1619.	0.4	0
448	Dose Coverage Beyond the Gross Tumor Volume for Various Stereotactic Body Radiotherapy Planning Techniques Reporting Similar Control Rates for Stage I Nonâ€“Small-Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2008, 72, 1597-1603.	0.4	21
449	Prospective Evaluation of Quality of Life and Neurocognitive Effects in Patients With Multiple Brain Metastases Receiving Whole-Brain Radiotherapy With or Without Thalidomide on Radiation Therapy Oncology Group (RTOG) Trial 0118. International Journal of Radiation Oncology Biology Physics, 2008, 71, 71-78.	0.4	86
450	A Phase III Study of Conventional Radiation Therapy Plus Thalidomide Versus Conventional Radiation Therapy for Multiple Brain Metastases (RTOG 0118). International Journal of Radiation Oncology Biology Physics, 2008, 71, 79-86.	0.4	91

#	Article	IF	Citations
451	Relationship Between Neurocognitive Function and Quality of Life After Whole-Brain Radiotherapy in Patients With Brain Metastasis. International Journal of Radiation Oncology Biology Physics, 2008, 71, 64-70.	0.4	259
452	In Reply to Drs. Weltman and Brandt. International Journal of Radiation Oncology Biology Physics, 2008, 70, 1292-1293.	0.4	0
453	Anaplastic Oligodendroglial Tumors: Refining the Correlation among Histopathology, 1p 19q Deletion and Clinical Outcome in Intergroup Radiation Therapy Oncology Group Trial 9402. Brain Pathology, 2008, 18, 360-369.	2.1	125
454	Radiation Oncology Advances: An Introduction. Cancer Treatment and Research, 2008, 139, 1-4.	0.2	5
455	Recurrence following neurosurgeon-determined gross-total resection of adult supratentorial low-grade glioma: results of a prospective clinical trial. Journal of Neurosurgery, 2008, 109, 835-841.	0.9	264
456	A New Prognostic Index and Comparison to Three Other Indices for Patients With Brain Metastases: An Analysis of 1,960 Patients in the RTOG Database. International Journal of Radiation Oncology Biology Physics, 2008, 70, 510-514.	0.4	907
457	Correlation of O⁶-Methylguanine Methyltransferase (MGMT) Promoter Methylation With Clinical Outcomes in Glioblastoma and Clinical Strategies to Modulate MGMT Activity. Journal of Clinical Oncology, 2008, 26, 4189-4199.	0.8	725
458	Dose Escalated, Hypofractionated Radiotherapy Using Helical Tomotherapy for Inoperable Non-Small Cell Lung Cancer: Preliminary Results of a Risk-Stratified Phase I Dose Escalation Study. Technology in Cancer Research and Treatment, 2008, 7, 441-447.	0.8	65
459	Progression-free survival: An important end point in evaluating therapy for recurrent high-grade gliomas. Neuro-Oncology, 2008, 10, 162-170.	0.6	362
460	Neurooncology clinical trial design for targeted therapies: Lessons learned from the North American Brain Tumor Consortium. Neuro-Oncology, 2008, 10, 631-642.	0.6	27
461	The impact of linac output variations on dose distributions in helical tomotherapy. Physics in Medicine and Biology, 2008, 53, 417-430.	1.6	18
462	Motexafin gadolinium and involved field radiation therapy for intrinsic pontine glioma of childhood: A Children's Oncology Group phase I study. Neuro-Oncology, 2008, 10, 752-758.	0.6	47
463	Improvement, Clinical Course, and Quality of Life After Palliative Radiotherapy for Recurrent Glioblastoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2008, 31, 300-305.	0.6	94
464	Combined Chemoradiotherapy Advances. Cancer Treatment and Research, 2008, , 277-301.	0.2	1
465	Stereotactic Body Radiation Therapy: Fractionated Radiation Therapy Perspective. , 2008, , 635-642.		0
466	Cost-Effectiveness and Quality of Life. , 2008, , 663-671.		0
467	Resection versus radiosurgery for patients with brain metastases. Future Oncology, 2007, 3, 95-102.	1.1	12
468	Motexafin gadolinium: a novel radiosensitizer for brain tumors. Expert Review of Anticancer Therapy, 2007, 7, 785-794.	1.1	23

#	Article	IF	Citations
469	Targeted Therapy for Brain Metastases: Improving the Therapeutic Ratio. Clinical Cancer Research, 2007, 13, 1675-1683.	3.2	67
470	Pharmacokinetic and Tumor Distribution Characteristics of Temsirolimus in Patients with Recurrent Malignant Glioma. Clinical Cancer Research, 2007, 13, 7401-7406.	3.2	74
471	Helical Tomotherapy: Image Guidance and Adaptive Dose Guidance. , 2007, 40, 162-178.		28
472	Megavoltage Computed Tomography. American Journal of Clinical Oncology: Cancer Clinical Trials, 2007, 30, 617-623.	0.6	31
473	Role of radiation therapy in treating intracranial meningiomas. Neurosurgical Focus, 2007, 23, E4.	1.0	64
474	Regression After Whole-Brain Radiation Therapy for Brain Metastases Correlates With Survival and Improved Neurocognitive Function. Journal of Clinical Oncology, 2007, 25, 1260-1266.	0.8	299
475	Motexafin gadolinium in the treatment of brain metastases. Expert Opinion on Pharmacotherapy, 2007, 8, 351-359.	0.9	30
476	Advances in Radiation Therapy for Brain Tumors. Neurologic Clinics, 2007, 25, 1005-1033.	0.8	24
477	B1-07: Decreased neurocognitive progression with Motexafin Gadolinium (MGd) plus Whole Brain Radiation Therapy (WBRT) in non-small cell lung cancer (NSCLC) patients with brain metastases: pooled analysis of two randomized phase 3 trials. Journal of Thoracic Oncology, 2007, 2, S335-S336.	0.5	0
478	PD5-2-8: Predictors of survival for non-small-cell lung cancer patients with brain metastases treated with whole brain radiation therapy: pooled data from two randomized trials. Journal of Thoracic Oncology, 2007, 2, S478.	0.5	0
479	Therapeutic management of metastatic brain tumors. Critical Reviews in Oncology/Hematology, 2007, 61, 70-78.	2.0	37
480	Impact of hybrid fluorodeoxyglucose positron-emission tomography/computed tomography on radiotherapy planning in esophageal and nonâ€"small-cell lung cancer. International Journal of Radiation Oncology Biology Physics, 2007, 67, 187-195.	0.4	93
481	Randomized Phase II Trial of High-Dose Melatonin and Radiation Therapy for RPA Class 2 Patients With Brain Metastases (RTOG 0119). International Journal of Radiation Oncology Biology Physics, 2007, 68, 852-857.	0.4	46
482	Distribution of Brain Metastases in Relation to the Hippocampus: Implications for Neurocognitive Functional Preservation. International Journal of Radiation Oncology Biology Physics, 2007, 68, 971-977.	0.4	168
483	Breathing-Synchronized Delivery: A Potential Four-Dimensional Tomotherapy Treatment Technique. International Journal of Radiation Oncology Biology Physics, 2007, 68, 1572-1578.	0.4	25
484	Results of the Phase I Dose-Escalating Study of Motexafin Gadolinium With Standard Radiotherapy in Patients With Glioblastoma Multiforme. International Journal of Radiation Oncology Biology Physics, 2007, 69, 831-838.	0.4	38
485	Whole Brain Radiotherapy With Hippocampal Avoidance and Simultaneously Integrated Brain Metastases Boost: A Planning Study. International Journal of Radiation Oncology Biology Physics, 2007, 69, 589-597.	0.4	176
486	A Prospective Study Comparing CT-Based to PET/CT-based Radiation Treatment Planning. International Journal of Radiation Oncology Biology Physics, 2007, 69, S68-S69.	0.4	1

#	Article	IF	Citations
487	Adaptive Tomotherapy Planning for Integrated Boost Doses in Rapidly Responding Lung Cancers. International Journal of Radiation Oncology Biology Physics, 2007, 69, S525.	0.4	0
488	Dosimetric Evaluation of Helical IMRT, Traditional IMRT and 3-D Conformal Radiation for Inoperable Non-Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2007, 69, S632-S633.	0.4	2
489	Whole Brain Radiation Therapy With Hippocampal Avoidance and Simultaneously Integrated Brain Metastases Boost With Helical Tomotherapy: A Planning Study. International Journal of Radiation Oncology Biology Physics, 2007, 69, S674-S675.	0.4	3
490	Therapeutic advances for glioblastoma multiforme: Current status and future prospects. Current Oncology Reports, 2007, 9, 66-70.	1.8	49
491	Impact of molecular profiling on clinical trial design for glioblastoma. Current Oncology Reports, 2007, 9, 71-79.	1.8	9
492	Radiation for Brain Metastases. Cancer Treatment and Research, 2007, 136, 91-115.	0.2	1
493	Advances in the Treatment of Brain Metastases. Translational Medicine Series, 2007, , 207-230.	0.0	0
494	Therapeutic advances in the treatment of brain metastases. Clinical Advances in Hematology and Oncology, 2007, 5, 54-64.	0.3	41
495	Radiotherapy and radiosensitizers in the treatment of glioblastoma multiforme. Clinical Advances in Hematology and Oncology, 2007, 5, 894-902, 907-15.	0.3	58
496	Motexafin-Gadolinium Taken Up In vitro by at Least 90% of Glioblastoma Cell Nuclei. Clinical Cancer Research, 2006, 12, 206-213.	3.2	52
497	Comparison of linac based fractionated stereotactic radiotherapy and tomotherapy treatment plans for skull-base tumors. Radiotherapy and Oncology, 2006, 78, 313-321.	0.3	54
498	Whole-Brain Radiotherapy in the Management of Brain Metastasis. Journal of Clinical Oncology, 2006, 24, 1295-1304.	0.8	431
499	Phase III Trial of Chemotherapy Plus Radiotherapy Compared With Radiotherapy Alone for Pure and Mixed Anaplastic Oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. Journal of Clinical Oncology, 2006, 24, 2707-2714.	0.8	678
500	How Can Tumor Effect and Normal Tissue Effect Be Balanced in Stereotactic Body Radiotherapy. , 2006, 6, 86-97.		1
501	Temozolomide as Prophylaxis for Brain Metastasis in Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2006, 1, 732-733.	0.5	6
502	Should concomitant and adjuvant treatment with temozolomide be used as standard therapy in patients with anaplastic glioma?. Critical Reviews in Oncology/Hematology, 2006, 60, 99-111.	2.0	32
503	Integral radiation dose to normal structures with conformal external beam radiation. International Journal of Radiation Oncology Biology Physics, 2006, 64, 962-967.	0.4	139
504	Helical tomotherapy as a means of administering total or partial scalp irradiation: In regards to Bedford et al. (Int J Radiat Oncol Biol Phys 2005;62:1549â€“1558). International Journal of Radiation Oncology Biology Physics, 2006, 64, 1288-1289.	0.4	7

#	Article	IF	Citations
505	A phase II trial of accelerated radiotherapy using weekly stereotactic conformal boost for supratentorial glioblastoma multiforme: RTOG 0023. International Journal of Radiation Oncology Biology Physics, 2006, 65, 1422-1428.	0.4	92
506	Tumor volume changes on serial imaging with megavoltage CT for nonâ€"small-cell lung cancer during intensity-modulated radiotherapy: How reliable, consistent, and meaningful is the effect?. International Journal of Radiation Oncology Biology Physics, 2006, 66, 135-141.	0.4	110
507	In response to Dr. PeÃ±agarÃcano. International Journal of Radiation Oncology Biology Physics, 2006, 65, 1274-1275.	0.4	1
508	Phase II Radiation Therapy Oncology Group trial of conventional radiation therapy followed by treatment with recombinant interferon-Î² for supratentorial glioblastoma: Results of RTOG 9710. International Journal of Radiation Oncology Biology Physics, 2006, 66, 818-824.	0.4	51
509	1014. International Journal of Radiation Oncology Biology Physics, 2006, 66, S136-S137.	0.4	3
510	1110. International Journal of Radiation Oncology Biology Physics, 2006, 66, S193-S194.	0.4	1
511	1115. International Journal of Radiation Oncology Biology Physics, 2006, 66, S196.	0.4	0
512	Tomotherapy and Other Innovative IMRT Delivery Systems. Seminars in Radiation Oncology, 2006, 16, 199-208.	1.0	71
513	Feasibility report of image guided stereotactic body radiotherapy (IG-SBRT) with tomotherapy for early stage medically inoperable lung cancer using extreme hypofractionation. Acta OncolÃ³gica, 2006, 45, 890-896.	0.8	71
514	A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: A North American Brain Tumor Consortium study1. Neuro-Oncology, 2006, 8, 189-193.	0.6	200
515	Clinical Implementation of Adaptive Helical Tomotherapy: A Unique Approach to Image-Guided Intensity Modulated Radiotherapy. Technology in Cancer Research and Treatment, 2006, 5, 465-479.	0.8	83
516	Phase I/II Study of Imatinib Mesylate for Recurrent Malignant Gliomas: North American Brain Tumor Consortium Study 99-08. Clinical Cancer Research, 2006, 12, 4899-4907.	3.2	404
517	Phase II Trial of Tipifarnib in Patients With Recurrent Malignant Glioma Either Receiving or Not Receiving Enzyme-Inducing Antiepileptic Drugs: A North American Brain Tumor Consortium Study. Journal of Clinical Oncology, 2006, 24, 3651-3656.	0.8	151
518	Primary Central Nervous System Lymphoma: The Memorial Sloan-Kettering Cancer Center Prognostic Model. Journal of Clinical Oncology, 2006, 24, 5711-5715.	0.8	500
519	Models Support Prophylactic Cranial Irradiation. Journal of Clinical Oncology, 2006, 24, 3524-3526.	0.8	21
520	Temozolomide-Mediated Radiation Enhancement in Glioblastoma: A Report on Underlying Mechanisms. Clinical Cancer Research, 2006, 12, 4738-4746.	3.2	195
521	Phase 2 trial of radiation plus high-dose tamoxifen for glioblastoma multiforme: RTOG protocol BR-00211. Neuro-Oncology, 2006, 8, 47-52.	0.6	53
522	SU-FF-T-369: Propagation of Linac Output and Fluence Discretization Error to Dose Distributions in IMRT. Medical Physics, 2006, 33, 2130-2131.	1.6	0

#	Article	IF	Citations
523	Linear Accelerator Radiosurgery for Trigeminal Neuralgia. Neurosurgery, 2005, 57, 1193-1200.	0.6	47
524	The impact of daily setup variations on head-and-neck intensity-modulated radiation therapy. International Journal of Radiation Oncology Biology Physics, 2005, 61, 779-788.	0.4	255
525	Accelerated hypofractionation. International Journal of Radiation Oncology Biology Physics, 2005, 61, 299-300.	0.4	3
526	Immunohistochemically determined total epidermal growth factor receptor levels not of prognostic value in newly diagnosed glioblastoma multiforme: Report from the Radiation Therapy Oncology Group. International Journal of Radiation Oncology Biology Physics, 2005, 62, 318-327.	0.4	45
527	Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: Report of Radiation Therapy Oncology Group 93-05 protocol: In regard to Souhami et al. (Int J Radiat Oncol Biol Phys 2004;60:853â€"860). International Journal of Radiation Oncology Biology Physics, 2005, 62, 296-297.	0.4	8
528	In response to Drs. Vordermark and KÃ¶lbl. International Journal of Radiation Oncology Biology Physics, 2005, 62, 297.	0.4	0
529	In regard to Dr. Souhami et al. (Int J Radiat Oncol Biol Phys 2004;60:853â€"860). International Journal of Radiation Oncology Biology Physics, 2005, 62, 614-615.	0.4	12
530	In reply to Dr. Kondziolka et al. International Journal of Radiation Oncology Biology Physics, 2005, 62, 615-616.	0.4	2
531	The American Society for Therapeutic Radiology and Oncology (ASTRO) evidence-based review of the role of radiosurgery for brain metastases. International Journal of Radiation Oncology Biology Physics, 2005, 63, 37-46.	0.4	321
532	The American Society for Therapeutic Radiology and Oncology (ASTRO) evidence-based review of the role of radiosurgery for malignant glioma. International Journal of Radiation Oncology Biology Physics, 2005, 63, 47-55.	0.4	162
533	Are More Aggressive Therapies Able to Improve Treatment of Locally Advanced Non-Small Cell Lung Cancer: Combined Modality Treatment?. Seminars in Oncology, 2005, 32, 25-34.	0.8	8
534	Potential for Radiation Therapy Technology Innovations to Permit Dose Escalation for Nonâ€"Small-Cell Lung Cancer. Clinical Lung Cancer, 2005, 7, 107-113.	1.1	13
535	Phase 1 study of concurrent RMP-7 and carboplatin with radiotherapy for children with newly diagnosed brainstem gliomas. Cancer, 2005, 104, 1281-1287.	2.0	37
536	A Phase I study of concurrent RMP-7 and carboplatin with radiation therapy for children with newly diagnosed brainstem gliomas. Cancer, 2005, 104, 1968-1974.	2.0	45
537	Secondary Analysis of Radiation Therapy Oncology Group study (RTOG) 9310: An Intergroup Phase II Combined Modality Treatment of Primary Central Nervous System Lymphoma. Journal of Neuro-Oncology, 2005, 74, 201-205.	1.4	86
538	Patterns of treatment failure in infants with primitive neuroectodermal tumors who were treated on CCG-921: A phase III combined modality study. Pediatric Blood and Cancer, 2005, 45, 676-682.	0.8	18
539	Current Strategies in Whole-brain Radiation Therapy for Brain Metastases. Neurosurgery, 2005, 57, S4-33-S4-44.	0.6	38
540	Helical Tomotherapy as a Means of Delivering Scalp-sparing Whole Brain Radiation Therapy. Technology in Cancer Research and Treatment, 2005, 4, 661-662.	0.8	14

#	Article	IF	Citations
541	Phase II Trial of Radiosurgery for One to Three Newly Diagnosed Brain Metastases From Renal Cell Carcinoma, Melanoma, and Sarcoma: An Eastern Cooperative Oncology Group Study (E 6397). Journal of Clinical Oncology, 2005, 23, 8870-8876.	0.8	176
542	Phase III Study of the Eastern Cooperative Oncology Group (ECOG 2597): Induction Chemotherapy Followed by Either Standard Thoracic Radiotherapy or Hyperfractionated Accelerated Radiotherapy for Patients With Unresectable Stage IIIA and B Nonâ€"Small-Cell Lung Cancer. Journal of Clinical Oncology, 2005, 23, 3760-3767.	0.8	151
543	Radiation Therapy for Leptomeningeal Cancer. , 2005, 125, 147-158.		22
544	Phase I Trial of Tipifarnib in Patients With Recurrent Malignant Glioma Taking Enzyme-Inducing Antiepileptic Drugs: A North American Brain Tumor Consortium Study. Journal of Clinical Oncology, 2005, 23, 6647-6656.	0.8	61
545	Are gadolinium contrast agents suitable for gadolinium neutron capture therapy?. Neurological Research, 2005, 27, 387-398.	0.6	58
546	Strategies for enhanced radiation delivery in patients with lung cancer. Expert Opinion on Drug Delivery, 2005, 2, 103-113.	2.4	3
547	Current Management of Brain Metastases, With a Focus on Systemic Options. Journal of Clinical Oncology, 2005, 23, 6207-6219.	0.8	334
548	Walking Forward: The South Dakota Native American Project. Journal of Cancer Education, 2005, 20, 65-70.	0.6	29
549	Basic Concepts Underlying Radiation Therapy. , 2005, , 70-74.		0
550	Phase II Study of Fenretinide (NSC 374551) in Adults With Recurrent Malignant Gliomas: A North American Brain Tumor Consortium Study. Journal of Clinical Oncology, 2004, 22, 4282-4289.	0.8	79
551	Helical Tomotherapy as a Means of Delivering Accelerated Partial Breast Irradiation. Technology in Cancer Research and Treatment, 2004, 3, 639-646.	0.8	41
552	The Impact of Mid-Treatment MRI on Defining Boost Volumes in the Radiation Treatment of Glioblastoma Multiforme. Technology in Cancer Research and Treatment, 2004, 3, 303-307.	0.8	32
553	Increasing Access to Clinical Cancer Trials and Emerging Technologies for Minority Populations: The Native American Project. Journal of Clinical Oncology, 2004, 22, 4452-4455.	0.8	41
554	Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: A North American Brain Tumor Consortium study. Neuro-Oncology, 2004, 6, 44-54.	0.6	70
555	Neurocognitive Function and Progression in Patients With Brain Metastases Treated With Whole-Brain Radiation and Motexafin Gadolinium: Results of a Randomized Phase III Trial. Journal of Clinical Oncology, 2004, 22, 157-165.	0.8	523
556	Treatment of malignant gliomas: radiotherapy, chemotherapy and integration of new targeted agents. Expert Review of Neurotherapeutics, 2004, 4, 691-703.	1.4	18
557	Analysis of 1p, 19q, 9p, and 10q as prognostic markers for high-grade astrocytomas using fluorescence in situ hybridization on tissue microarrays from Radiation Therapy Oncology Group trials. Neuro-Oncology, 2004, 6, 96-103.	0.6	55
558	Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study. Neuro-Oncology, 2004, 6, 33-37.	0.6	57

#	Article	IF	Citations
559	O 6-Benzylguanine suppression of O6-alkylguanine-DNA alkyltransferase in anaplastic gliomas. Neuro-Oncology, 2004, 6, 28-32.	0.6	31
560	Management of brain metastases. Seminars in Oncology, 2004, 31, 693-701.	0.8	98
561	Megavoltage Computed Tomography Imaging: A Potential Tool to Guide and Improve the Delivery of Thoracic Radiation Therapy. Clinical Lung Cancer, 2004, 5, 303-306.	1.1	48
562	Phase I study pilot arms of radiotherapy and carmustine with temozolomide for anaplastic astrocytoma (Radiation Therapy Oncology Group 9813): implications for studies testing initial treatment of brain tumors. International Journal of Radiation Oncology Biology Physics, 2004, 59, 1122-1126.	0.4	17
563	Patterns of failure in supratentorial primitive neuroectodermal tumors treated in Children's Cancer Group Study 921, a phase III combined modality study. International Journal of Radiation Oncology Biology Physics, 2004, 60, 204-213.	0.4	31
564	Phase II study of neoadjuvant 1, 3-bis (2-chloroethyl)-1-nitrosourea and temozolomide for newly diagnosed anaplastic glioma. Cancer, 2004, 100, 1712-1716.	2.0	49
565	Feasibility of neurocognitive outcome evaluations in patients with brain metastases in a multi-institutional cooperative group setting: results of Radiation Therapy Oncology Group trial BR-0018. International Journal of Radiation Oncology Biology Physics, 2004, 58, 1346-1352.	0.4	81
566	The contribution of epidermal growth factor receptor (EGFR) signaling pathway to radioresistance in human gliomas: a review of preclinical and correlative clinical data. International Journal of Radiation Oncology Biology Physics, 2004, 58, 927-931.	0.4	121
567	Continuous 28-day iododeoxyuridine infusion and hyperfractionated accelerated radiotherapy for malignant glioma: a phase I clinical study. International Journal of Radiation Oncology Biology Physics, 2004, 59, 1107-1115.	0.4	18
568	Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: Report of Radiation Therapy Oncology Group 93-05 protocol. International Journal of Radiation Oncology Biology Physics, 2004, 60, 853-860.	0.4	527
569	A challenge to traditional radiation oncology. International Journal of Radiation Oncology Biology Physics, 2004, 60, 1241-1256.	0.4	273
570	American Society for Therapeutic Radiology and Oncology* and American College of Radiology Practice Guideline for the Performance of Stereotactic Body Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2004, 60, 1026-1032.	0.4	191
571	The utility of megavoltage computed tomography images from a helical tomotherapy system for setup verification purposes. International Journal of Radiation Oncology Biology Physics, 2004, 60, 1639-1644.	0.4	137
572	Chemoradiation for upper aerodigestive tract cancer: balancing evidence from clinical trials with individual patient recommendations. Current Problems in Cancer, 2004, 28, 7-40.	1.0	17
573	A phase I study of Topotecan, as a radiosensitizer, for thoracic malignancies. Lung Cancer, 2004, 44, 111-119.	0.9	6
574	Motexafin gadolinium: a clinical review of a novel radioenhancer for brain tumors. Expert Review of Anticancer Therapy, 2004, 4, 981-989.	1.1	41
575	Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet, The, 2004, 363, 1665-1672.	6.3	2,248
576	Novel radiosensitizers for tumors of the central nervous system. Current Opinion in Investigational Drugs, 2004, 5, 1284-91.	2.3	2

#	Article	IF	Citations
577	A study of a different dose-intense infusion schedule of phenylacetate in patients with recurrent primary brain tumors consortium report. Investigational New Drugs, 2003, 21, 429-433.	1.2	6
578	Combined modality treatment for central nervous system malignancies. Seminars in Oncology, 2003, 30, 11-22.	0.8	15
579	Image guidance for precise conformal radiotherapy. International Journal of Radiation Oncology Biology Physics, 2003, 56, 89-105.	0.4	445
580	Craniospinal treatment with the patient supine. Medical Dosimetry, 2003, 28, 35-38.	0.4	23
581	Clinical promise tempered by reality in the delivery of combined chemoradiation for common solid tumors. Seminars in Radiation Oncology, 2003, 13, 3-12.	1.0	20
582	E-53. Helical tomotherapy: An innovative technological radiation therapeutic approach for lung cancer. Lung Cancer, 2003, 41, S67-S68.	0.9	0
583	Phase III Study Comparing Three Cycles of Infusional Carmustine and Cisplatin Followed by Radiation Therapy With Radiation Therapy and Concurrent Carmustine in Patients With Newly Diagnosed Supratentorial Glioblastoma Multiforme: Eastern Cooperative Oncology Group Trial 2394. Journal of Clinical Oncology, 2003, 21, 1485-1491.	0.8	130
584	RSR13 Plus Cranial Radiation Therapy in Patients With Brain Metastases: Comparison With the Radiation Therapy Oncology Group Recursive Partitioning Analysis Brain Metastases Database. Journal of Clinical Oncology, 2003, 21, 2364-2371.	0.8	101
585	Survival and Neurologic Outcomes in a Randomized Trial of Motexafin Gadolinium and Whole-Brain Radiation Therapy in Brain Metastases. Journal of Clinical Oncology, 2003, 21, 2529-2536.	0.8	438
586	Phase II Evaluation of Temozolomide and 13-cis-Retinoic Acid for the Treatment of Recurrent and Progressive Malignant Glioma: A North American Brain Tumor Consortium Study. Journal of Clinical Oncology, 2003, 21, 2305-2311.	0.8	151
587	Gentlemen (and Ladies), Choose your Weapons: Gamma Knife vs. Linear Accelerator Radiosurgery. Technology in Cancer Research and Treatment, 2003, 2, 79-85.	0.8	32
588	A phase I study of topotecan as a radiosensitizer for brainstem glioma of childhood: First report of the Children's Cancer Group-0952. Neuro-Oncology, 2003, 5, 8-13.	0.6	39
589	Reduction in Radiation Dose to Lung and Other Normal Tissues Using Helical Tomotherapy to Treat Lung Cancer, in Comparison to Conventional Field Arrangements. American Journal of Clinical Oncology: Cancer Clinical Trials, 2003, 26, 70-78.	0.6	80
590	Title is missing!. American Journal of Clinical Oncology: Cancer Clinical Trials, 2003, 26, 273-279.	0.6	13
591	Neurocognitive and Functional Assessment of Patients With Brain Metastases. American Journal of Clinical Oncology: Cancer Clinical Trials, 2003, 26, 273-279.	0.6	70
592	Treatment of brain metastases: a short review of current therapies and the emerging role of temozolomide. Clinical Advances in Hematology and Oncology, 2003, 1, 231-6.	0.3	6
593	Helical Tomotherapy: An Innovative Technology and Approach to Radiation Therapy. Technology in Cancer Research and Treatment, 2002, 1, 311-316.	0.8	149
594	Fractionated Stereotactic Radiotherapy: A Short Review. Technology in Cancer Research and Treatment, 2002, 1, 153-172.	0.8	25

#	Article	IF	Citations
595	Lead-In Phase to Randomized Trial of Motexafin Gadolinium and Whole-Brain Radiation for Patients With Brain Metastases: Centralized Assessment of Magnetic Resonance Imaging, Neurocognitive, and Neurologic End Points. Journal of Clinical Oncology, 2002, 20, 3445-3453.	0.8	141
596	A phase II trial of thymidine and carboplatin for recurrent malignant glioma: A North American Brain Tumor Consortium Study. Neuro-Oncology, 2002, 4, 109-114.	0.6	46
597	Neurocognitive sequelae of cancer treatment. Neurology, 2002, 59, 8-10.	1.5	38
598	Trastuzumab for Breast Cancerâ€"Related Carcinomatous Meningitis. Clinical Breast Cancer, 2002, 2, 316.	1.1	17
599	Three-dimensional conformal radiotherapy for lung cancer: Promises and pitfalls. Current Oncology Reports, 2002, 4, 347-353.	1.8	8
600	Pineal Sarcoma. Acta Neurochirurgica, 2002, 144, 89-92.	0.9	4
601	Retrospective vs. randomized data: the prevalence of bias. in response to Drs. Millar and Laperriere. International Journal of Radiation Oncology Biology Physics, 2002, 53, 252-253.	0.4	0
602	A multi-institutional review of radiosurgery alone vs. radiosurgery with whole brain radiotherapy as the initial management of brain metastases. International Journal of Radiation Oncology Biology Physics, 2002, 53, 519-526.	0.4	515
603	What is the appropriate primary end point for clinical trials for patients with brain metastases? In Response to Drs. Burri and Asher. International Journal of Radiation Oncology Biology Physics, 2002, 53, 1394.	0.4	4
604	LINAC-based radiosurgery in the treatment of trigeminal neuralgia: a preliminary report. International Journal of Radiation Oncology Biology Physics, 2002, 54, 303-304.	0.4	1
605	A phase II trial of thymidine and carboplatin for recurrent malignant glioma: a North American Brain Tumor Consortium Study. Neuro-Oncology, 2002, 4, 109-14.	0.6	6
606	Optically guided intensity modulated radiotherapy. Radiotherapy and Oncology, 2001, 61, 33-44.	0.3	45
607	Multicenter Phase Ib/II Trial of the Radiation Enhancer Motexafin Gadolinium in Patients With Brain Metastases. Journal of Clinical Oncology, 2001, 19, 2074-2083.	0.8	126
608	Late Recurrence of a Primitive Neuro-Ectodermal Tumor. Oncology, 2001, 61, 189-191.	0.9	4
609	Multiple daily fractionation radiotherapy schedules in lung cancer. Current Oncology Reports, 2001, 3, 179-184.	1.8	4
610	A new approach to dose escalation in nonâ€"small-cell lung cancer. International Journal of Radiation Oncology Biology Physics, 2001, 49, 23-33.	0.4	241
611	Quality of life assessment in advanced non-small-cell lung cancer patients undergoing an accelerated radiotherapy regimen: report of ECOG study 4593. International Journal of Radiation Oncology Biology Physics, 2001, 50, 1199-1206.	0.4	37
612	A Phase II study of paclitaxel in patients with recurrent malignant glioma using different doses depending upon the concomitant use of anticonvulsants. Cancer, 2001, 91, 417-422.	2.0	88

#	Article	IF	Citations
613	Assessment of patient-independent intrinsic error for a noninvasive frame for fractionated stereotactic radiotherapy. International Journal of Cancer, 2001, 96, 320-325.	2.3	15
614	Radiosurgery for patients with brain metastases: a multi-institutional analysis, stratified by the RTOG recursive partitioning analysis method. International Journal of Radiation Oncology Biology Physics, 2001, 51, 426-434.	0.4	261
615	A phase II study of preradiation chemotherapy followed by external beam radiotherapy for the treatment of patients with newly diagnosed glioblastoma multiforme: an Eastern Cooperative Oncology Group study (E2393). Journal of Neuro-Oncology, 2000, 47, 145-152.	1.4	32
616	Radiotherapy for brain tumors. Current Oncology Reports, 2000, 2, 438-444.	1.8	11
617	Pilot and Safety Trial of Carboplatin, Paclitaxel, and Thalidomide in Advanced Nonâ€"Small-Cell Lung Cancer. Clinical Lung Cancer, 2000, 2, 48-52.	1.1	25
618	Phase II Study of Phenylacetate in Patients With Recurrent Malignant Glioma: A North American Brain Tumor Consortium Report. Journal of Clinical Oncology, 1999, 17, 984-984.	0.8	70
619	Phase I Trial of Intravenous Thymidine and Carboplatin in Patients With Advanced Cancer. Journal of Clinical Oncology, 1999, 17, 2922-2922.	0.8	7
620	Radiosurgery for Brain Metastases. Neurosurgery Clinics of North America, 1999, 10, 337-350.	0.8	35
621	Recurrent Malignant Gliomas Treated with Radiosurgery. Journal of Radiosurgery, 1999, 2, 119-125.	0.1	13
622	Comparison of Methods for Response Analysis of Central Nervous System Neoplasms. Journal of Radiosurgery, 1999, 2, 153-161.	0.1	3
623	Tomotherapy. Seminars in Radiation Oncology, 1999, 9, 108-117.	1.0	390
624	Development of a Unique Phantom to Assess the Geometric Accuracy of Magnetic Resonance Imaging for Stereotactic Localization. Neurosurgery, 1999, 45, 1423-1431.	0.6	68
625	Stereotactic Irradiation. American Journal of Clinical Oncology: Cancer Clinical Trials, 1999, 22, 143-146.	0.6	25
626	The Status of Stereotactic Radiosurgery for Cerebral Metastases in 1998. Journal of Radiosurgery, 1998, 1, 17-30.	0.1	11
627	On â€œStereotactic Radiosurgery for Patients with Single Brain Metastasisâ€•(Cho et al., This Issue). Journal of Radiosurgery, 1998, 1, 87-88.	0.1	0
628	Phase I study of paclitaxel in patients with recurrent malignant glioma: a North American Brain Tumor Consortium report.. Journal of Clinical Oncology, 1998, 16, 2188-2194.	0.8	122
629	Phase II trial of hyperfractionated accelerated radiation therapy for nonresectable non-small-cell lung cancer: results of Eastern Cooperative Oncology Group 4593.. Journal of Clinical Oncology, 1998, 16, 3518-3523.	0.8	55
630	Dimension in defining tumor response.. Journal of Clinical Oncology, 1998, 16, 1234-1234.	0.8	20

#	Article	IF	Citations
631	Effect of amifostine on toxicities associated with sequential chemotherapy and radiation therapy for unresectable non-small-cell lung cancer: results of a phase II trial.. Journal of Clinical Oncology, 1997, 15, 2850-2857.	0.8	67
632	A cost-effectiveness and cost-utility analysis of radiosurgery vs. resection for single-brain metastases. International Journal of Radiation Oncology Biology Physics, 1997, 39, 445-454.	0.4	195
633	The effect of M-stage on patterns of failure in posterior fossa primitive neuroectodermal tumors treated on CCG-921: A phase III study in a high-risk patient population. International Journal of Radiation Oncology Biology Physics, 1997, 38, 469-475.	0.4	39
634	214 Endobronchial and endoesophageal high dose rate brachytherapy for malignant airway and digestive tract obstructions. International Journal of Radiation Oncology Biology Physics, 1997, 39, 123.	0.4	0
635	19 Feasibility & acute toxicities of craniospinal hyperfractionated radiotherapy (CHFRT) for high risk intracranial primitive neuroectodermal tumors (HRPNET); CCG-9931; A groupwide phase II study of intensive chemotherapy (CT) & CHFRT. International Journal of Radiation Oncology Biology Physics, 1997, 39, 144.	0.4	0
636	1021 Optic nerve tolerance to single and fractionated radiation simulating radiosurgery: A rabbit model using visual evoked potentials, fundoscopy and histology. International Journal of Radiation Oncology Biology Physics, 1997, 39, 226.	0.4	0
637	1034 Experience with the functional assessment of cancer therapy-lung (FACT-L) in ecog 4593, a phase II hyperfractionated accelerated radiation therapy (HART) trial. International Journal of Radiation Oncology Biology Physics, 1997, 39, 232.	0.4	0
638	Thorotrast-associated Oropharyngeal Hemorrhage: Treatment by Means of Carotid Occlusion with Use of Flow Arrest and Fibered Coils. Journal of Vascular and Interventional Radiology, 1996, 7, 709-712.	0.2	4
639	Phase II study of paclitaxel in patients with recurrent malignant glioma.. Journal of Clinical Oncology, 1996, 14, 2316-2321.	0.8	87
640	Localized 2DJ-resolved H MR spectroscopy of human brain tumorsin vivo. Journal of Magnetic Resonance Imaging, 1996, 6, 453-459.	1.9	87
641	Manpower issues and training program directions in radiation oncology. International Journal of Radiation Oncology Biology Physics, 1996, 34, 970.	0.4	0
642	A multiinstitutional outcome and prognostic factor analysis of radiosurgery for resectable single brain metastasis. International Journal of Radiation Oncology Biology Physics, 1996, 35, 27-35.	0.4	517
643	The potential of topoisomerase I inhibitors in the treatment of CNS malignancies: report of a synergistic effect between topotecan and radiation. Journal of Neuro-Oncology, 1996, 30, 1-6.	1.4	48
644	Stereotactic radiosurgery for glioblastoma: a final report of 31 patients. Journal of Neurosurgery, 1995, 82, 530-535.	0.9	93
645	Linear accelerator configurations for radiosurgery. Seminars in Radiation Oncology, 1995, 5, 203-212.	1.0	17
646	The physical, biologic, and clinical basis of radiosurgery. Current Problems in Cancer, 1995, 19, 270-328.	1.0	32
647	Radiosurgery in the initial management of malignant gliomas: Survival comparison with the RTOG recursive partitioning analysis. International Journal of Radiation Oncology Biology Physics, 1995, 32, 931-941.	0.4	175
648	Glioblastoma multiforme: â€œwho should receive stereotactic boost therapy?â€• International Journal of Radiation Oncology Biology Physics, 1994, 30, 746.	0.4	0

#	Article	IF	Citations
649	Stereotactic radiosurgery improves survival in malignant gliomas compared with the RTOG recursive partitioning analysis. International Journal of Radiation Oncology Biology Physics, 1994, 30, 164-165.	0.4	7
650	Stereotactic radiosurgery for glioblastoma multiforme: Report of a prospective study evaluating prognostic factors and analyzing long-term survival advantage. International Journal of Radiation Oncology Biology Physics, 1994, 30, 541-549.	0.4	146
651	Current radiosurgery practice: results of an astro survey. International Journal of Radiation Oncology Biology Physics, 1994, 28, 523-526.	0.4	50
652	Consensus statement on stereotactic radiosurgery quality improvement. International Journal of Radiation Oncology Biology Physics, 1994, 28, 527-530.	0.4	26
653	Stereotactic Radiosurgery for Glioblastoma multiforme. Stereotactic and Functional Neurosurgery, 1994, 63, 233-240.	0.8	5
654	Thoracic volume radiation sparing following endobronchial brachytherapy: A quantitative analysis. International Journal of Radiation Oncology Biology Physics, 1993, 25, 703-707.	0.4	22
655	Treatment of arteriovenous malformations with stereotactic radiosurgery employing both magnetic resonance angiography and standard angiography as a database. International Journal of Radiation Oncology Biology Physics, 1993, 25, 309-313.	0.4	54
656	Inguinofemoral radiation of N0,N1 vulvar cancer may be equivalent to lymphadenectomy if proper radiation technique is used. International Journal of Radiation Oncology Biology Physics, 1993, 27, 963-967.	0.4	78
657	Response to editorial by Drs. Lanciano and corn. International Journal of Radiation Oncology Biology Physics, 1993, 27, 991.	0.4	0
658	Consensus guidelines for high dose rate remote brachytherapy in cervical, endometrial, and endobronchial tumors*. International Journal of Radiation Oncology Biology Physics, 1993, 27, 1241-1244.	0.4	53
659	Acute changes in glucose uptake after treatment: the effects of carmustine (BCNU) on human glioblastoma multiforme. Journal of Neuro-Oncology, 1993, 15, 57-66.	1.4	33
660	Cavernous sinus cranial neuropathies: is there a dose-response relationship following radiosurgery?. International Journal of Radiation Oncology Biology Physics, 1993, 27, 477-480.	0.4	25
661	Magnetic resonance angiography: a three-dimensional database for assessing arteriovenous malformations. Journal of Neurosurgery, 1993, 79, 289-293.	0.9	29
662	A Retrospective Review of Nodal Treatment for Vulvar Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 1993, 16, 38-42.	0.6	39
663	Meningeal hemangiopericytoma: defining the role for radiation therapy. Journal of Neuro-Oncology, 1992, 14, 277-87.	1.4	68
664	Sequential comparison of low dose rate and hyperfractionated high dose rate endobronchial radiation for malignant airway occlusion. International Journal of Radiation Oncology Biology Physics, 1992, 23, 133-139.	0.4	63
665	Endobronchial brachytherapy: Wither prescription point. International Journal of Radiation Oncology Biology Physics, 1992, 23, 251.	0.4	1
666	Defining the role of radiosurgery in the management of brain metastases. International Journal of Radiation Oncology Biology Physics, 1992, 24, 619-625.	0.4	282

#	Article	IF	Citations
667	Treatment of WilmsÊ¼ Tumour. Drugs, 1991, 42, 766-780.	4.9	17
668	A three-dimensional volume visualization package applied to stereotactic radiosurgery treatment planning. International Journal of Radiation Oncology Biology Physics, 1991, 21, 491-500.	0.4	46
669	Early changes in tumor metabolism after treatment: The effects of stereotactic radiotherapy. International Journal of Radiation Oncology Biology Physics, 1991, 20, 1053-1060.	0.4	58
670	Effect of Endobronchial Radiation Therapy on Malignant Bronchial Obstruction. Chest, 1990, 97, 662-665.	0.4	46
671	Monte Carlo and convolution dosimetry for stereotactic radiosurgery. International Journal of Radiation Oncology Biology Physics, 1990, 19, 1027-1035.	0.4	49
672	Endobronchial irradiation: Is HDR better?. International Journal of Radiation Oncology Biology Physics, 1990, 19, 1629.	0.4	0
673	90Y Â· B72.3 Against pancreatic cancer: Dosimetric and biological analysis. International Journal of Radiation Oncology Biology Physics, 1990, 19, 627-631.	0.4	10
674	Minimization of small bowel volume within treatment fields utilizing customized â€œbelly boardsâ€• International Journal of Radiation Oncology Biology Physics, 1990, 19, 469-476.	0.4	99
675	Endobronchial irradiation for malignant airway obstruction. International Journal of Radiation Oncology Biology Physics, 1989, 17, 847-851.	0.4	59
676	Radiation induced thyroid neoplasms 1920 to 1987: A vanishing problem?. International Journal of Radiation Oncology Biology Physics, 1989, 16, 1471-1475.	0.4	31
677	Adult Wilms' Tumor: Role of Combined Modality Treatment. Acta OncolÃ³gica, 1989, 28, 647-650.	0.8	4
678	Treatment of Probable Subclinical Liver Metastases and Gross Pancreatic Carcinoma with Hepatic Artery 5-Fluorouracil Infusion and Radiation Therapy. Acta OncolÃ³gica, 1988, 27, 377-381.	0.8	13
679	Optimizing the Radiotherapy Treatment Planning Process for Glioblastoma. Neuro-Oncology Practice, 0, , .	1.0	0